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High-throughput genomic data contain gazillion of information that are influenced
by the complex biological processes in the cell. As such, appropriate mathematical
modeling frameworks are required to understand the data and the data generating
processes. This dissertation focuses on the formulation of mathematical models and
the description of appropriate computational algorithms to obtain insights from ge-
nomic data.
Specifically, characterization of intra-tumor heterogeneity is studied. Based on
the total number of allele copies at the genomic locations in the tumor subclones, the
problem is viewed from two perspectives: the presence or absence of copy-neutrality
assumption. With the presence of copy-neutrality, it is assumed that the genome
contains mutational variability and the three possible genotypes may be present at
each genomic location. As such, the genotypes of all the genomic locations in the
tumor subclones are modeled by a ternary matrix. In the second case, in addition to
mutational variability, it is assumed that the genomic locations may be affected by
structural variabilities such as copy number variation (CNV). Thus, the genotypes
are modeled with a pair of (Q+ 1)-ary matrices. Using the categorical Indian buffet
process (cIBP), state-space modeling framework is employed in describing the two
processes and the sequential Monte Carlo (SMC) methods for dynamic models are
applied to perform inference on important model parameters.
Moreover, the problem of estimating gene regulatory network (GRN) from mea-
surement with missing values is presented. Specifically, gene expression time series
data may contain missing values for entire expression values of a single point or some
set of consecutive time points. However, complete data is often needed to make infer-
ence on the underlying GRN. Using the missing measurement, a dynamic stochastic
model is used to describe the evolution of gene expression and point-based Gaussian
approximation (PBGA) filters with one-step or two-step missing measurements are
applied for the inference. Finally, the problem of deconvolving gene expression data
from complex heterogeneous biological samples is examined, where the observed data
are a mixture of different cell types. A statistical description of the problem is used
and the SMC method for static models is applied to estimate the cell-type specific
expressions and the cell type proportions in the heterogeneous samples.
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Chapter 1
Introduction
Deoxyribonucleic acid (DNA) is the repository of all biological information and the
order of arrangement of its bases determines the information to make proteins which
are the molecules that regulate all biological processes, ranging from survival, repro-
duction and regulation of other proteins [1]. The protein synthesis process involves
a two-step procedure: transcription (information from DNA is copied into a new
molecule of ribonucleic acid (RNA)) and translation (RNA form proteins). The en-
tire process is termed the central dogma of molecular biology [2]. The information
present at each stage of the process, when carefully accessed, are used to understand
the complex biological systems so as to prevent, identify, diagnose and potentially
develop treatments for several genetic diseases [3, 4].
High-throughput next-generation sequencing (NGS) and microarray technologies
have greatly improved the accuracy of biological signal measurements at every stage
of the protein synthesis process [5, 6]. Using these measurements, Computational biol-
ogy, a cross-subject area, focuses on the development and application of mathematical
modeling techniques to the study and understanding of the underlying biological sys-
tems [7]. Considering the biological hypotheses that have been proposed by biologists
and clinicians, computational scientists aim to develop specialized computational al-
gorithms to assess the complexity of biological systems.
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Cancer, a complex disease, involves multiple and specific changes at the DNA,
RNA and protein levels [8]. Currently, enormous computational efforts have been
devoted to the translational cancer research (TCR), whose insights hold the key to
the therapeutic progress in oncology [9, 10]. TCR seeks to identify and understand
the causes and effects of cancer-specific variations at different levels and to translate
this knowledge to the clinical application to improve cancer prevention, prognosis and
therapy [11].
In most cases, cancer-causing malignant tumors or tumors often develop from a
single population of cells. With time, accumulated somatic mutations confer selec-
tive advantages to the cells in this population over others [12], and this population of
cells continues to proliferate. As more somatic mutations are acquired, some tumor
cells gain further survival advantages and this leads to an expansion from a single
population to multiple subpopulations of cancerous cells. As a result, tumors are
heterogeneous [13, 14] with multiple subpopulations of cancerous cells, each with a
unique profile of genotypes [15, 16], referred to as tumor subclones [17]. Charac-
terization of tumor heterogeneity by analyzing the tumor subclonal structure and
evolutionary progress is an important problem in TCR since it possesses the poten-
tial to elucidate the underlying mechanisms of cancer progression, metastatic spread
and therapy response [18].
In recent years, various types of biological data including single cell sequenc-
ing (SCS) and bulk sample sequencing (BSS) data have been generated [19] to aid
an accurate characterization of tumor heterogeneity. Armed with these rich data,
in particular, BSS, the objective is to develop computational algorithms to resolve
tumor heterogeneity. Based on the assumption on the allele copy numbers at the
genomic locations in the tumor subclones, the problem is divided into two: resolving
tumor heterogeneity in the presence or absence of copy-neutrality assumption. In the
first case, it is assumed that the maximum number of allele copies at every genomic
location in each of the tumor subclones is two. The copy-neutrality assumption en-
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sures that the solution to the problem will be limited to finding the possible number
of tumor subclones, the mutational profile of every subclone and the proportion of
each subclone in the tumor samples. In the second case, due to high instabilities
observed in cancer genome, events such as copy number variation (CNV) abound and
this breaks the copy-neutrality assumption. Hence, by extension, allele copy numbers
at each genomic location is estimated in addition to the estimation of the number
of subclones, subclonal proportions and number of variant alleles in each genomic
location.
Moreover, almost any biological activity is reflected in a changing gene expression
pattern. Thus, gene expression is considered as a sensitive indicator of the complex
biological activities, processes and change in any organism. Oftentimes, RNA-Seq
and microarray technologies are used to obtain information on the expression level of
genes [20, 21]. Now, an interesting problem in Computational biology is to determine
which genes and other molecular regulators interact with each to control a specific
cell function, a phenomenon referred to as gene regulatory network (GRN). GRNs
are often re-engineered using the gene expression data. However, the problem be-
comes complicated when, for example, in a time series gene expression data, data for
certain time points are missing. This significantly affects the performance of many
algorithms for gene expression analysis that take as an input, the complete matrix of
gene expression measurement. Till date, few algorithms have been proposed for the
inference of gene regulatory network from gene expression data with missing values.
Another important objective in gene expression studies involves identification of
genes that are differentially expressed between groups of samples, such as case versus
control or normal versus tumor tissue. Most of the time, the gene expression data
employed in performing this task are a mixture of different cell types. This heteroge-
nous nature imposes some difficulties in the analysis of such data and as a result, it
becomes increasingly difficult to draw any meaningful conclusion from the data. In
resolving the inherent heterogeneity, methods like microdissection and flow cytometry
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are used to physically separate the heterogeneous samples to constituting cell types
[22]. However, manual separation methods are time consuming and exposed samples
often get contaminated with external perturbations which results in altered yield of
molecular content. A computational approach for resolving sample heterogeneity of
gene expression data and thereby circumventing the aforementioned issues is termed
gene expression deconvolution (GED). A GED algorithm ensures that the complex
samples are resolved to the constituting cell-type specific gene expressions and cell
type proportions for further analyses.
This thesis focuses on addressing the above-mentioned problems, one after the
other, using appropriate biological data. In each case, we proposed adequate math-
ematical modeling framework to describe the data generation process and described
suitable computational algorithms to perform inference on model parameters.
1.1 Thesis Overview
This thesis is divided into two parts namely: (i) characterization of intra-tumor het-
erogeneity with DNA sequencing data and (ii) modeling gene expression data: GRN
and GED. The first part comprises of Chapters 2 and 3 and the second part comprises
of Chapters 4 and 5.
1.1.1 Characterization of intra-tumor heterogeneity with
DNA sequencing data
In Chapters 2 and 3, using DNA sequencing data from BSS, we presented modeling
frameworks and computational algorithms for characterizing intra-tumor heterogene-
ity from variant allele fractions (VAFs) of somatic mutations, with and without using
the copy-neutrality assumption. Our modeling approach considered the state-space
formulation of the feature allocation models and its flexibility guarantees that VAFs
from as many genomic locations as possible can be processed. For estimation, we
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employed the sequential Monte Carlo (SMC) method for dynamic models to jointly
estimate all the hidden state variables and parameters of our state-space models.
Our proposed SMC algorithms take advantage of the categorical Indian buffet pro-
cess (cIBP) [23], a sequential procedure that describes the prior distribution of the
general (Q+1)-ary categorical matrix, in modeling the genotypes of tumor subclones.
More details about the state variables, model parameters and results obtained in both
cases will follow.
In Chapter 2, making use of the copy-neutrality assumption, our proposed algo-
rithm estimated the number, genotypes and the proportion of tumor subclones in
tumor samples. We achieved this by deconvolving the observed VAFs data into geno-
type and proportion matrices. Our solution allowed more categories for the genotypes,
so as to capture the three possible genotypes in a diploid individual. Specifically, in
modeling the genotypes, we considered 0, 0.5 and 1 for the homozygous wild-type,
heterozygous mutant and homozygous mutant, respectively. In our state-space for-
mulation for this case, we considered each row of the genotype matrix as the hidden
state of the system at a time step, and the proportion matrix and other param-
eters are considered as the parameters of the system. With extensive simulation,
the proposed solution, when compared with other methods, produced high accuracy.
Also, we validated our solution through analyzing real tumor samples from patients
from multiple cancer types (breast, prostate, and lung). The results revealed driver
mutation events specific to cancer types, and indicate clonal expansion by manual
phylogenetic analysis.
In Chapter 3, we relaxed such assumption as copy-neutrality. This allowed for
adequate consideration for structural variability such as CNV in our modeling strat-
egy. The proposed algorithm, using the VAFs data, estimated the number of tumor
subclones in addition to three distinct matrices: (i) a (Q+1)−ary matrix of subclonal
total allele copy numbers, (ii) a (Q+ 1)− ary matrix of subclonal variant allele copy
numbers (iii) and a matrix of subclone proportions in the samples. In our state-space
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formulation, each row of the subclonal total allele copy numbers and the subclonal
variant allele copy numbers matrices is considered as the hidden state of the system
at a time step, and we considered other model parameters, including the propor-
tion matrix, as the parameters of the system. Extensive simulation shows that the
proposed method yields better accuracy when compared with other state-of-the-art
methods for addressing similar problem. Also, further validation was done with real
data obtained from patients with high-grade serous ovarian cancers.
1.1.2 Modeling gene expression data: GRN and GED
In Chapter 4, we addressed the problem of re-engineering GRN from measurement
with missing values. First, we described a nonlinear dynamic stochastic model that
captures the structural, dynamical, and the nonlinear natures of the underlying
biomolecular systems for the evolution of gene expression. Next, we presented point-
based Gaussian Approximation (PBGA) filters using Gaussian approximation (GA)
and various quadrature rules, for state estimation from one-step or two-step randomly
delayed measurements. Our general framework involved augmenting the state vari-
ables with model parameters and we made Gaussian assumptions on the posterior
state and missing measurement. We used the inferred parameter set to identify the
underlying regulatory network structure. The proposed algorithm is evaluated with
satisfying results for synthetic networks, in-silico networks released as a part of the
DREAM project, and the real biological network, the in vivo reverse engineering and
modeling assessment (IRMA) network of yeast Saccharomyces cerevisiae.
Gene expression data from pure samples with a single cell type, when analyzed,
will produce a significant amount of information. However, reverse is the case when
the samples are highly heterogeneous. As a result, prior to further analyses, the sam-
ples need to be separated so as to obtain the expressions and contributions of the con-
stituting cell types. In Chapter 5, we presented our solution to the problem of GED.
Specifically, we modeled the heterogeneous gene expression data using a Bayesian
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framework. In particular, we viewed the cell type proportions and the cell-type spe-
cific expressions as the parameters of the model and appropriate prior distributions
were assumed for all these parameters. To make inference on the model parame-
ters, we employed the SMC sampler for static models to obtain samples from their
posterior distributions. Our proposed algorithm is evaluated on simulated datasets
and publicly available real biological datasets namely: (i) Affymetrix oligonucleotide
arrays and (ii) national center for biotechnology information (NCBI) gene expression
omnibus (GEO). When compared to other widely known methods for blind decom-
position of heterogeneous gene expression data, the proposed algorithm showed a
superior performance with an improved accuracy in the estimation of cell type pro-
portions and the cell-type specific expressions and also, produced a more accurate
identification of differentially expressed genes.
Each chapter is self-contained and can be read independently, presented with a
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Chapter 2
A sequential Monte Carlo
algorithm for inference of
subclonal structure in cancer
2.1 Introduction
In most cases, tumors develop from a single population of cells. Accumulated somatic
mutations confer selective advantages to the cells in this population over others [12],
and then this population of cells continues to proliferate. As more somatic mutations
are acquired, some tumor cells gain further survival advantages, which leads to an
expansion from a single population to multiple subpopulations. As a result, tumors
are heterogeneous in nature [13, 14] and contain multiple subpopulations of cancerous
cells, each with a unique mutational profile [15, 16, 24], referred to as tumor subclones
[13, 17, 25]. The importance of analyzing the tumor subclonal structure and evo-
lutionary progress has been recognized, considering the potential of elucidating the
underlying mechanisms of cancer progression, metastatic spread and therapy response
[18, 26, 27].
Characterizing tumor heterogeneity with subclonal structure, using next genera-
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tion sequencing (NGS) data is a well-studied problem [28], and various computational
methods have been proposed for estimating the subclonal structure in the tumor sam-
ples [29–33]. Some methods approach this estimation problem by first grouping the
mutations into clusters, and then performing phylogenetic analysis to obtain the mu-
tational profiles of the various distinct subclones in the samples [30–33]. A more direct
approach bypasses the clustering stage by modeling, in straightforward manner, the
NGS data with a feature allocation model [29, 34–36]. Basically, with this setup,
the problem is reduced into a form of matrix factorization [37], where the observed
variant allele frequency (VAF) is deconvolved into matrices of genotypes of subclones
and the proportion of genotypes in the samples [29, 34, 36]. However, methods in
this category are faced with several issues, such as the assumption that the number
of subclones have to be fixed before analysis [29, 35], and the fact that only a few
mutations can be analyzed [35].
Here, we propose an algorithm for estimating the number, genotypes and the
proportion of subclones, employing a more general model that better explains the in-
herent heterogeneity in tumor samples by allowing more categories for the genotypes,
so as to capture the three possible genotypes in a diploid individual. Specifically, 0 for
homozygous wild-type, 0.5 for heterozygous mutant and 1 for homozygous mutant.
Our approach, which is based on the state-space formulation of the feature alloca-
tion model, employs the SMC [38, 39] algorithm for estimating the model parameters.
The proposed SMC algorithm takes advantage of the categorical Indian buffet pro-
cess (cIBP) [36], a sequential procedure that describes the prior distribution of the
general (Q + 1)-ary categorical matrix, in modeling the genotypes of subclones. Be-
cause the proposed algorithm processes the observed VAF data sequentially, it offers
the flexibility of being able to handle any number of mutations without encountering
computational issues. More specifically, SMC, a powerful recursive filtering algorithm
[37, 40, 41], computes, in a flexible manner, the posterior probability density function
(PDF) of the hidden state every time a measurement is observed, approximating the
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posterior distributions of the variables of interest with a set of properly weighted
samples, which we will refer to as particles to distinguish between random samples
from a distribution and tumor samples.
Over the simulated datasets, we compare our algorithm with BayClone [36], a
Markov chain Monte Carlo (MCMC) based algorithm, often employed when estimat-
ing model parameters in tumor heterogeneity [35], and Clomial [29], an expectation
maximization (EM) based algorithm. Similar to the our modeling method, BayClone
considers the three possible genotypes in a diploid individual. Although the modeling
approach in Clomial only considers homozygous wild-type and heterozygous mutant
(a common modeling consideration in the analysis of tumor heterogeneity [35]), it em-
ploys EM, a different inference algorithm, to estimate the model parameters. Invari-
ably, our simulations compare the performance of three different algorithms: SMC,
MCMC and EM. In terms of the accuracy of the estimates of model parameters, the
proposed SMC method compares favorably with other methods.
The remainder of this chapter is organized as follows. In Section 2.2, we describe
the system model and problem formulation. In Section Section 2.3, we validate the
proposed algorithm with simulated data, as well as real data obtained from solid
tumors across three major cancer types: prostate adenocarcinoma (PRAD), breast
invasive ductal carcinoma (IDC) and lung adenocarcinoma (LUAD). Finally, Sec-
tion 2.4 concludes the chapter.
Notation-wise in this chapter, we denote a vector and a matrix by boldface lower
and upper case letters, respectively; p(·) and p(·|·) denote a probability density func-
tion (PDF) and a conditional PDF, respectively; P (·) and P (·|·) denote a probability
and conditional probability mass function, respectively; N (µ, σ2) denotes a Gaussian
distribution with mean µ and standard deviation σ; Binomial(n, p) denotes a binomial
distribution having n number of trials and p probability of success; Poisson(λ) denotes
a Poisson distribution with mean parameter λ; Gamma(a0, b0) denotes a gamma dis-
tribution with shape parameter a0 and rate parameter b0; Beta(a1, b1) denotes a beta
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distribution with shape parameters a1 and b1 and Dirichlet(α) denotes a Dirichlet
distribution with a vector of concentration parameters α.
2.2 System model and problem formulation
2.2.1 System model
In our model, we assume that a tumor is heterogeneous i.e., it consists of multiple
sub-populations, referred to as subclones. Each subclone is assumed to have a unique
genotype and at each characterizing mutation locus, we assume that one of the follow-
ing is the case: (i) none of the alleles is mutated (homozygous wild-type), designated
with genotype 0, (ii) one of the alleles is mutated, designated with genotype 0.5, and
(iii) both alleles are mutated, designated with genotype 1. Our goal is to estimate
the number of subclones, genotypes of all the subclones, and the proportion of each
subclone in the tumor samples. To do this, we assume an availability of DNA se-
quencing data designed to probe tumor heterogeneity. This dataset comes in form of
two matrices Y and V of equal dimension T ×S. T and S denote the numbers of loci
and tumor samples, respectively, and the elements of the two input matrices, yts and
vts, t = 1, ..., T, s = 1, ..., S, denote the number of reads that bear a variant sequence
and the total number of reads, respectively. We model the matrix of variant counts
as follows:
yts
ind.∼ Binomial(vts, pts), t = 1, ..., T, s = 1, ..., S, (2.1)
where pts is the success probability of obtaining yts reads from the total reads vts at
locus t in sample s, t = 1, ..., T, s = 1, ..., S. pts is interpreted as the weighted sum of





where C denotes the unknown number of distinct subclones in the tumor samples,
ztc ∈ {0, 0.5, 1} denotes the possible three states for the allelic genotypes at locus
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t in subclone c and wcs denotes the proportion of subclone c in tumor sample s.
In addition, the first term in (2.2) accounts for experimental and data processing
noise, where p denotes the relative frequency of variant reads produced as error from
upstream data processing and usually takes a small value, close to zero; w0s absorbs
the noise left unaccounted for by {w1s, ..., wCs} [36].
In (2.2), for all the genomic loci, we arrange the genotypes of all subclones in a
T × C ternary matrix Z and we refer to this as the matrix of genotypes. Similarly,
we arrange all the p’s in a T -dimensional column vector p, and arrange the respective
proportions w0s and wcs, for all samples, in a C
′ × S matrix W and refer to this as
the matrix of proportions, where each column of the proportion matrix sums to unity,
and C
′




where pts, an element of Pts, denotes the expected VAF at locus t in sample s and
Z′ = [p Z]. Given the input read count data, we next describe the proposed SMC
algorithm to perform a joint inference on the number of distinct subclones in the
tumor samples, the genotype of each subclone and the proportion of each genotype
in the tumor samples.
2.2.2 State-space formulation
In this section, we succinctly describe our state-space formulation of the deconvolution
problem we set up in (2.3). At time step t, we consider the tth row of the input read
count matrices, as the observation at that particular time. Subsequently, because
we are interested in constructing the ternary genotype matrix Z (with an unknown
number of columns) sequentially, one row after the other, using the cIBP (see the
Supplementary Material in [42]), we consider the tth row of the genotype matrix as
the hidden state at time t, and then, the proportion of the subclones in the tumor
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samples, matrix W and p are considered as the parameters of our state-space model.
Thus, the state transition equation is stated as follows:
P (zt|Zt−1, α, β), (2.4)
where Zt−1 denotes the previous t − 1 rows in the genotype matrix Z, α and β are
constants, to be supplied by the user. The reasonable range for both constants are
discussed in the Supplementary Material in [42] and the algorithm to sample from
(2.4) is presented in Algorithm 1 as follows.
The genotype matrix at time step t, Zt is implicitly constructed from the genotype
matrix in the previous time step t − 1, Zt−1. In the construction process, if new
non-zero column(s) is/are introduced in Zt, then the subclone proportion matrix W
would be augmented with an equivalent number of rows. Thus, W requires some
re-parameterization to account for such change in dimension. Specifically, we rewrite
wcs = θcs/
∑C
c′=0 θc′s. This implies that instead of estimating wcs directly, we estimate
θcs, and then obtain wcs from the estimates of θcs. Such re-parameterization ensures
that each column of W sums to unity at every time step.
Moreover, since we are interested in the final estimates of the model parameters
W and p, we create artificial dynamics for these parameters using the random walk
model as follows:
φt ∼ p(φt|φt−1) = N (φt−1, σ2),
φt ∈ {p, θcs, c = 0, 1, ..., C, s = 1, ..., S},
(2.5)
where σ denotes the standard deviation. Hence, (2.4)-(2.5) fully describe the system
state transition. Similarly, the observation at time t is given by:






where yt denotes the observation at time t (which is conditionally independent of the
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Algorithm 1 Sample P (zt|Zt−1, α, β) using the categorical Indian buffet process
(cIBP).
1: Z← Zt−1
2: β∗ = 2β
3: if t = 1 then
4: Sample Cnewt ∼ Poisson(α)














9: C+ ← Number of non-zero columns in Z
10: for c = 1, ..., C+ do
11: mc1 ←
∑t−1
r=1 I(zrc = 0.5)
12: mc2 ←
∑t−1
r=1 I(zrc = 1)
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previous observations Yt−1 given the state zt), i.e., the tth row of Y. (2.6) describes
the measurement model for the system. Finally, (2.4) - (2.6) completely describe our
proposed state-space model for estimating the number, genotypes and proportions of
subclones in tumor samples.
2.2.3 The SMC algorithm
We summarize the SMC filtering framework employed to make inference about the
number of subclones, genotype of each subclone and the proportion of each subclone
in the tumor samples, which are the states and the parameters of our proposed state-
space model. Details of our proposed algorithm are presented in the Supplementary
Material in [42].
Consider the general dynamic system with hidden state variable xt, in our case
consisting of categorical variables zt and continuous variables φt, φt ∈ {pt0, θtcs, c =
0, 1, ..., C, s = 1, ..., S}, and measurement variable yt, where there is an initial state
model p(x0), and ∀t ≥ 1, a state transition model given in (2.4) - (2.5) and an
observation model given in (2.6). The sequence Xt = {x1,x2, ...,xt} is not observed
and we want to estimate it for each time step, given that we have the observations
Yt = {y1,y2, ...,yt}. Our goal is to approximate the posterior distribution of states
p(Xt|Yt) using samples drawn from it. Getting such samples from p(Xt|Yt) is not
feasible, at least in our model. However, we can still implement an estimate using
N samples (particles), {Xit}Ni=1, taken from another distribution, q(Xt|Yt), whose
support includes the support of p(Xt|Yt) (importance sampling theorem), and each
particle is accompanied by a weight wi such that
∑N
i=1wi = 1. Thus, the pair
{Xit, wi1:t}Ni=1 is said to be properly weighted with respect to the distribution p(Xt|Yt),




witδ(Xt −Xit), where δ(u) =
1, if u = 00, otherwise. (2.7)
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Algorithm 2 SMC algorithm for inferring subclonal structure.
1: Input: Y, V.
2: Initialize N particles {zi0, pi0,Wi0}Ni=1
3: for t = 1, ..., T do
4: for i = 1, ..., N do
5: Sample zit from Z
i
t−1 using Algorithm 1
6: n1 ← number of columns in Zit−1
7: n2 ← length of zit
8: d← (n2 − n1)













14: Sample Wit using (2.5).
15: Sample new rows of Wit from the prior in (2.9).
16: end if
17: Calculate w˜it using (2.8)
18: end for
19: Normalize the weights
20: Perform resampling
21: end for
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Next, the importance sampling theory is generalized to obtain a sequential algo-
rithm as follows. We assume that, at time step t − 1, we have already drawn the
weighted particles {Xit−1, wit−1}Ni=1 from the importance distribution q(Xt−1|Yt−1) to
approximate the target posterior distribution p(Xt−1|Yt−1). At time step t, we can
now draw particles {Xit}Ni=1 from the importance distribution q(Xt|Yt) as follows: (i)
draw new state particles for the time step t as xit ∼ p(xt|Xit−1) from (2.4) - (2.5),
and (ii) write {Xit}Ni=1 = {xit,Xit−1}Ni=1. Then, the unnormalized weights at time step
t are obtained from the normalized weights at time step t− 1 and the measurement




and the unnormalized weights w˜it are normalized to sum to unity. However, since the
variance of the weights increases over time, we perform resampling at every time step,
owing to the choice of our importance distribution [43–46], discarding the ineffective
particles and multiplying the effective ones. The resampling procedure [40] is briefly
summarized as follows:
• Interpret each weight wit as the probability of obtaining the particle index i.
• Draw N particles from the discrete probability distribution {wit} and replace
the old particle set with this new one.
• Set all weights to the constant value wit = 1/N .
Finally, the proposed SMC algorithm for estimating the states and the parameters
of our state-space model is presented in Algorithm 2. The algorithm is initialized
by taking samples from the prior distributions of the parameters. We assume the
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following:
θi0s
i.i.d∼ Gamma(a0, 1), s = 1, ..., S,
θics
i.i.d∼ Gamma(a1, 1), s = 1, ..., S, c = 1, ..., C, and
pi ∼ Beta(a00, b00),
(2.9)










c′s = 1. We report the
posterior estimates of all the unknown variables using the procedure highlighted in
[47].
2.3 Results
2.3.1 Application to simulated datasets
To validate our method, we generated multiple simulated datasets for different com-
binations of the number of subclones C, average sequencing depth r, sample size
S and the number of loci T . Specifically, we considered C ∈ {3, 4, 5} subclones,
S ∈ {3, 4, ..., 15} tumor samples, we fixed the average sequencing depth r = 100 and
also the number of loci, T = 20. For each combination of the number of subclones,
sample size, average sequencing depth and number of loci, we produced 10 datasets
as follows: (i) the total read count at locus t in sample s, i.e., vts is generated from
Poisson(r), (ii) each column of the proportion matrix is independently generated from
Dirichlet([a0, a1, ..., aC ]), a0 = 0.1 and ac, c ∈ {1, ..., C} is randomly chosen from the
set {2, 4, 5, 6, 7, 8}, (iii) each entry of the genotype matrix is independently gener-
ated from Discrete([0.5 0.1 0.4]) and set p = 0.02, (iv) the success probability pts is
computed following (5.2), and then, (v) yts, the variant count, is generated as an
independent sample from Binomial(vts, pts).
To quantify the performance of the proposed algorithm, we define the following
metrics: genotype reconstruction error (eZ), proportion error (eW ) and the error of
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Figure 2.1: Simulation results for the proposed algorithm. (a), (b) and (c):
Plots of the genotype error (eZ), proportion error (eW ) and error of success probability
(epts) versus different sample sizes for subclones C ∈ {3, 4, 5}. (d), (e) and (f):
Posterior distributions of C, for C = 3, 4, and 5.
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However, because this is a blind decomposition, it is not clear a priori which column
of the estimated genotype matrix Zˆ corresponds to which column of the true genotype
matrix Z. We resolve this by calculating eZ with every permutation of the columns
of Zˆ and then select the permutation that results in the smallest value. The selected
permutation is then used in computing eW and epts .
For every combination of the number of subclones, sample size, average sequencing
depth and number of loci, we computed the average and the standard deviation of
the genotype error, proportion error and the error of the success probabilities over
the 10 datasets in each group. The results are presented in Figure 2.1 (a - c) where
the standard deviation is the vertical line above and below the average value in the
errorbar plots. These results show that the performance of the proposed algorithm
improves with an increase in the number of tumor samples. Also, when the number of
subclones in the samples is minimal, estimation of model parameters becomes more
accurate. For T = 20, r = 100, S = 10 and C ∈ {3, 4, 5}, we present, in Figure 2.1
(d - f), the estimated posterior distributions of C. In the three cases, the maximum
a posteriori (MAP) estimates of C (marked with red vertical lines) are 3, 4 and 5. It
should be noted that in the implementation of the proposed algorithm, the estimates
of other model parameters are conditional on the MAP estimate of C.
Further, we compared our proposed algorithm with BayClone [36], an algorithm
with similar model assumption and also with Clomial [29]. For the comparison with
Clomial, the true genotype matrix only includes two categories i.e. 0 for an absence
of mutation and 0.5 for the presence of mutation and each entry of the matrix is
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Figure 2.2: The proposed algorithm and BayClone. (a), (b) and (c): Plots of
the genotype error (eZ), proportion error (eW ) and error of success probability (epts)
versus different sample sizes for the proposed algorithm and BayClone.
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Figure 2.3: The proposed algorithm and Clomial. (a) and (b): Plots of the
genotype error (eZ) and proportion error (eW ) versus different sample sizes for the
proposed algorithm and Clomial.
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Table 2.1: Comparison of algorithms on large datasets.
Genotype error Proportion error Runtimes (seconds)
Proposed algorithm 0.0040 [0.0050] 0.0121 [0.0116] 2.754e4 [5.707e4]
BayClone 0.1000 [0.0950] 0.0632 [0.0724] 5.032e4 [1.363e5]
Clomial 0.0850 [0.0500] 0.0548 [0.0550] 2.736e4 [5.688e4]
generated from Discrete([0.3 0.7]). In computing the errors for Clomial, we viewed
a 1 in the estimated genotype matrix as 0.5 for consistency with the true matrix.
The results of the simulated data for three subclones, different sample size, average
sequencing depth of 100 and 50 loci are presented in Figures 2.2 and 2.3. Figure 2.3
does not include the error of success probability because Clomial only estimates the
genotype and the proportion matrices. The runtime for the proposed algorithm,
BayClone and Clomial for sample size S = 5, number of subclones C = 3, average
sequencing depth r = 100 and 50 loci are 782, 1454 and 768 seconds, respectively, on
a 3.5 GHz Intel 8 cores running MATLAB. Lastly, we investigated the performance
of the algorithms when the number of loci is very large since this is often a source
of computational issue in some of the existing methods [35]. The result for 2000 and
5000 genomic loci are presented in Table 2.1 (the results for 2000 and 5000 loci are
with and without brackets, respectively). For the proposed algorithm, we noticed a
slight improvement in the estimate of the proportion when the number of loci is large.
In the case of the two other algorithms, we observed a slight increase in the genotype
and proportion errors with large genomic loci.
2.3.2 Application to solid tumor datasets
2.3.2.1 Data pre-processing
The somatic mutation data of real solid tumors come from the American Association
for Cancer Research (AACR) Genomics Evidence Neoplasia Information Exchange
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(GENIE) project [1]: Version 2.0.0, which are accessible on the Sage Synapse platform
(with Synapse ID: syn11310744) [48]. We performed three filtering criteria before
creating the final data set to run our algorithm. (i) The data release includes genomic
records collected by eight participating institutions. To control the batch effect, we
selected samples from Memorial Sloan Kettering (MSK) Cancer Center given the fact
that they provide matched tumor-normal (rather than tumor-only) sequence data
and their sample size is the largest. (ii) We selected patients who have at least three
samples with somatic mutation data. (iii) We further filtered out samples so that
the remaining data contain information for at least three patients for each cancer
type. As a result, the data set we retained include 36 samples (of 10 patients) with
prostate adenocarcinoma (PRAD), 18 samples (of 6 patients) with breast invasive
ductal carcinoma (IDC) and 9 samples (of 3 patients) with lung adenocarcinoma
(LUAD).
To create the input count matrices for the proposed algorithm, we combined count
data of all the samples from the same patient by the union of their mutated gene
symbols. Regarding the entries for which the mutation of the corresponding gene
was not detected in some samples, we imputed the values with the average counts of
the matched normal samples. For instance, we assume that there are three samples
(A, B, C) from a specific patient and samples A and B have mutations at gene G
while sample C does not. In the combined total (or alteration) count matrix of this
patient, we used the average of total (or alteration) counts for gene G of the matched
normal samples of A and B to be the imputed count of C for gene G in the combined
matrices.
2.3.2.2 Inferred subclonal structure and phylogenetic trees
We illustrated the use of our algorithm on the three solid cancer types: PRAD,
IDC and LUAD. We applied our algorithm on the data of every patient, resulting in
the inferred subclonal landscape, which contains the information of the genotypes,
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the proportions of each subclone as well as the possible phylogenetic tree. Some of
the model parameter estimates are presented and the others, including the posterior
distributions of the number of subclones, are in the Supplementary Material in [42].
A phylogenetic tree depicts the evolutionary history of cancer progression. Based
on the inferred subclonal genotypes, drawing insight from the approach in [29], we
manually constructed a phylogenetic tree for each patient, in which the root is always
the normal subclone, each node represents a subclonal population, and the mutations
that occurred between the parent and the offspring nodes are shown on the edges.
Moreover, since our algorithm is able to identify both heterozygous and homozy-
gous mutations, we annotated those mutations which were inferred as homozygous.
We reasoned that investigating the subclonal results combined with the phylogenetic
characteristics has the potential to provide evidence for the validity of our method.
2.3.2.3 Driver mutations found on edges connected to the root of the
phylogenetic trees
We observed that genes with well known driver mutations for one cancer type are
located on the edges that are connected to the root of the phylogenetic tree of patients
with that cancer. This is consistent with the fact that are somatic mutations in a gene
that confer a selective advantage on cancer cells, which are believed to be involved in
cancer initiation and clonal expansions [49].
Specifically, in each of the six instances of IDC, we found that either gene PIK3CA
or gene AKT1 is placed on the edge directly connected to the neutral/normal sub-
clone. Two examples are shown in Figures 2.4 (IDC 0000525) and 2.5 (IDC 0000690)
and the corresponding estimated genotype matrices are shown in Tables 2.2 and 2.3,
respectively. The inferred results for other IDC patients can be found in the Supple-
mentary Material in [42]. Somatic mutations occurring in oncogenes PIK3CA and
AKT1 have been widely reported in breast cancer [50–52]. PIK3CA is the most fre-
quently mutated gene found in breast cancer [53], and it is an integral component of
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Figure 2.4: Phylogenetic tree for IDC 0000525. Constructed phylogenetic tree
for patient IDC 0000525.
the phosphatidylinositol 3 kinase (PI3K) signaling pathway. AKT1, one of the three
isoforms of the protein kinase AKT, is also a mediator in the downstream of the PI3K
pathway and it plays a key role in promoting cell survival by inhibiting apoptosis. Its
over-activation has been implicated in tumorigenesis [51–54]. The dysregulation of
the PI3K/AKT pathway has been demonstrated in different solid tumors including
breast cancer, and it has been suggested that this dysregulation is associated with
the increased mutations in pathway genes PIK3CA and AKT1 [52, 55].
In the case of LUAD, KRAS and EGFR have mutations found prevalent in patients
[56–58]. Despite the small number of patients, the constructed phylogenetic trees
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Figure 2.5: Phylogenetic tree for IDC 0000690. Constructed phylogenetic tree
for patient IDC 0000690.
showed consistent results. First, among the three LUAD patients, two of them harbor
somatically mutant KRAS and the remaining one has mutation in EGFR, which
also reflects the well-known mutual exclusiveness of these two driver mutations [59].
Figure 2.6 and Table 2.4 display the case of patient LUAD 0000978, from which we
can find that KRAS is marked on the edge connected to the root in the phylogenetic
tree, indicating its oncogenic role. A previous study analyzing somatic mutation data
of non-small cell lung cancer by a different method also found that KRAS and EGFR
mutations were present in the founder clone in their results, suggesting that it is likely
that these mutations are initiating events for lung cancer [56].
2.3.2.4 Genotype assignments validated by the tree structures
One of the advantages of the proposed algorithm is that for each gene, it can consider
three different categories of genotype: wild-type, heterozygous and homozygous. This
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Figure 2.6: Phylogenetic tree for LUAD 0000978. Constructed phylogenetic
tree for patient LUAD 0000978.
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Table 2.2: Estimated genotype for IDC 0000525.
Gene name C1 C2 C3 C4
TP53 0 0.5 0 0.5
AKT1 0.5 0.5 0.5 0.5
RUNX1 0.5 0 0.5 0
POLE 0 0.5 0 0.5
FANCC 0 0 0 0.5
STK11 0 0 0 0.5
EP300 0 0 0 0.5
RB1 0 0.5 0 0
FOXP1 0.5 0 0.5 0
SHQ1 0 0.5 0 0
Table 2.3: Estimated genotype for IDC 0000690.




feature was validated by analyzing the hierarchical structure of the inferred phylo-
genetic trees. Given that one of our assumptions is that a mutation never disap-
pears in the entire phylogeny, if a mutant gene were assigned different genotypes in
different subclones, the subclone(s) with homozygous mutations should be descen-
dant(s) of the subclone(s) with heterozygous mutations. This implies that the pater-
nal and the maternal alleles (or vice versa) of this gene became mutated consecutively,
along the clonal evolution. Such situations apply to three cases of PRAD patients:
PRAD 0000655, PRAD 0003101, PRAD 0003511 (Figure 2.7), constructed from the
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Table 2.4: Estimated genotype for LUAD 0000978.
Gene name C1 C2 C3 C4
SMAD4 1 0 0 0
PTPRT 0.5 0 0 0
RAD54L 1 0 0 0
APC 0.5 0.5 0 0
GRIN2A 0.5 0.5 0 0
PAK7 0.5 0 0 0
MET 0.5 0.5 0.5 0
KRAS 0 0 0 0.5
inferred genotype matrices in the Supplementary Material in [42]. For example, in
patient with ID “PRAD 0003101”, the inferred decomposition results in Supplemen-
tary Material in [42] showed that there are two subclones (referred to as subclone 1
and subclone 2, respectively) in addition to the normal one. Both subclone 1 and
subclone 2 harbor mutations in gene PTEN; however, the respective genotypes are
different: “0.5” (i.e. heterozygous) for subclone 1 while “1” (homozygous) for sub-
clone 2. The constructed phylogenetic tree revealed concordant result (Figure 2.7(b))
that subclone 2 is the offspring node of subclone 1, suggesting that an additional
mutation event occurred in PTEN during this clonal expansion which resulted in the
change in genotype.
2.3.2.5 Inferred subclonal proportions along the phylogeny indicate tu-
mor progression
Furthermore, the inferred subclonal proportions along with the tree structures provide
more evidence to validate our algorithm. For the same patient that we discussed
above i.e., “PRAD 0003101”, there are three metastatic samples available among
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Figure 2.7: Phylogenetic trees for patients with PRAD. Constructed phy-
logenetic tree for patients: (a) PRAD 0000655, (b) PRAD 0003101 and (c)
PRAD 0003511.
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which one was obtained when the patient was 68 years old (referred to as M1) and
the other two were obtained when he was 69 years old (referred to as M2 and M3).
We found that the proportions of subclone 2 in M2 (96%) and M3 (86%) samples
are much higher than the one for M1 sample (29%), and cases for subclone 1 to
the contrary Supplementary Material in [42]. Meanwhile, we also observed similar
results for another patient with ID “PRAD 0001204”, who has two primary tumor
samples and one metastatic sample (Supplementary Material in [42]). In this case,
subclone 1 descends from subclone 2, and the highest proportion of subclone 1 can
be found in the metastatic sample, which was also obtained when the patient was
older. These findings imply that as the patient aged or the cancer metastasized,
the mutations specific to the descendant subclone gained cells survival advantage,
promoting cell proliferation, and hence resulted in the increasing proportion of the
subclone in samples.
2.4 Discussion
The inherent heterogeneity in tumor samples often results in setbacks when cancer
patients undergo treatment. The samples consist of different subpopulations of can-
cerous cells, each characterized by a distinct mutational profile. Inference of these
profiles and the proportion of each subpopulation in the samples can improve per-
sonalized medicine e.g. preventing cancer relapse and helping in cancer prognosis.
We proposed an efficient sequential algorithm for estimating the mutational profile
of each cancer cell subpopulation and their respective proportions in the tumor sam-
ples. With simulated datasets, we performed experiments to validate our algorithm.
We applied our algorithm to real tumor samples, covering three solid cancer types,
PRAD, IDC, and LUAD.
By analyzing the inferred genotype landscape results, we found evidence support-
ing the validity of our method in several ways. For example, many well-known driver
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mutations specific to cancer types were found in the edges directly connected to the
root in the inferred phylogenetic tree. The position of these somatic mutations indi-
cates their roles in cancer initiation and expansion. For example, somatic mutations
in genes PIK3CA and AKT1 were identified as driver events for breast cancer, sug-
gesting malfunction of PI3K/AKT pathway in cancer [55]. Such characteristics were
consistently observed across different patients included in this study.
We also evaluated our algorithm by investigating the phylogenetic tree structures,
which could imply the cancer progression history in patients. The algorithm is able
to distinguish the genotype of a mutation among wild-type, heterozygous and ho-
mozygous. Consistent with one of our assumptions that a somatic mutation will not
disappear, our results revealed that if a mutant gene were assigned different geno-
types in different subclones, the subclone(s) with homozygous mutations was always
the descendant(s) of the subclone(s) with heterozygous mutations, indicating the or-
der of mutation events on different alleles during the clonal expansion. Moreover, we
observed increasing proportions of leaf subclones in more advanced samples than less
advanced ones, such as metastatic samples versus primary samples, from the identical
patients, suggesting the proliferation of cells in these subclones due to the survival
advantages by acquiring more mutations during the cancer progression [12].
Lastly, the proposed algorithm can handle any number of mutations in an accurate
and computationally efficient manner.
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Tumor heterogeneity includes inter-tumor (between tumors) and intra-tumor (within
a tumor) heterogeneity [60]. Research on inter-tumor heterogeneity has helped in
defining and identifying different cancer subtypes according to patients genomic pro-
files. Based on this, patients might be targeted with different clinical treatments
[61, 62]. However, such classifications based on inter-tumor heterogeneity are far
from sufficient to characterize tumors. Thus, understanding intra-tumor heterogene-
ity becomes crucial as it gives us opportunities to further learn how tumor evolves
in both temporal and spatial dimensions [13, 63]. A tumor lesion grows from a single
population of cells. Acquired somatic aberrations confer selective survival advantages
to the cells in this population over others, and this population of cells continues to
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proliferate and further expand to multiple subpopulations. Each subpopulation, re-
ferred to as a tumor subclone, is with a distinctive genotype [14, 25]. Considering the
close relationships between intra-tumor heterogeneity and cancer progression vis-a`-
vis resistance to therapy and recurrences [64], the importance of analyzing somatic
alterations to infer tumor subclonal structures has been recognized [65].
In recent years, intra-tumor heterogeneity has been investigated through the next-
generation sequencing (NGS) technology [13], e.g., by performing bulk tumor sequenc-
ing [63] or single-cell sequencing [66, 67] of tumor samples. Although the single-cell
sequencing approach elucidates a more direct way to study intra-tumor heterogene-
ity, data obtained from single-cell sequencing is still expensive and noisy [68]. Also,
out of the very large number of cells present in a tumor, only a few can be assessed
via single-cell sequencing [68]. On the other hand, bulk tumor sequencing presents
a faster and cost effective way to probe intra-tumor heterogeneity [14, 69, 70]. Bulk
tumor sequencing produces, at sample level, the read counts supporting a variant
and the total read counts at selected genomic locations, or simply, a fraction of the
variant and the total read counts, VAFs.
In the literature, various computational methods, with different simplified as-
sumptions about the selected genomic locations, have been proposed to characterize
intra-tumor heterogeneity, using the observed VAFs [28, 68]. In terms of the modeling
assumptions and estimated variables, these methods can be viewed from two perspec-
tives: (i) methods that model and reconstruct the evolutionary relationships among
distinct subclones in the tumor samples [71–73], and (ii) methods that estimate the
subclonal composition by identifying the unique features and the proportions of dis-
tinct subclones in the tumor samples (may or may not include manual reconstruction
of possible evolutionary relationship among subclones) [29–31, 74, 75]. Modeling the
evolutionary relationship among subclones has some advantages, such as, aiding the
prediction of disease development for future patients [76]. However, several issues
have been raised about the usage of inferred tumor phylogenies in making biological
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references about the evolutionary relationships among tumor subclones [47, 74, 77].
For example, in most cases, there is heavy reliance on the infinite-site assumption,
i.e., the assumption that during the evolutionary history of a tumor, a site is never
mutated twice. However, such assumption may be violated in tumors due to high
genomic instability [68].
On the other hand, a host of methods that estimate the genotype of each genomic
location in the subclones and the proportion of each subclone in the tumor samples do
not take cognizance of the structural variability/genetic instabilities in the genome
[29, 31, 74]. Events such as copy number variation (CNV) are common in cancer.
CNVs occurring at mutation loci could significantly complicate the decomposition of
observed VAFs. In [47], a feature allocation model was proposed to resolve intra-
tumor heterogeneity using the VAF data of somatic mutations without making the
copy-neutral assumption. In this framework, observed VAFs can be deconvolved into
three matrices. First, a matrix of the total copy numbers for each mutation locus
in each subclone. Second, a matrix of the copy numbers of variant allele for each
mutation locus in each subclone. Third, a matrix of subclonal proportions, describing
the cellular proportion of each subclone in each sample. To infer the unknown model
variables, [47] proposed a method, BayClone2, based on the Markov chain Monte
Carlo (MCMC) algorithm. However, the proposed solution in BayClone2 does not
accurately infer model parameters in real scenarios when there are limited number of
tumor samples. Also, when large number of genomic locations are probed, consistent
with whole genome or whole exome sequencing, BayClone2 suffers from technical and
computational issues [74]. Finally, if more genomic locations are probed for tumor
heterogeneity, there is no way to refine the existing estimates with the new VAFs
data.
In this chapter, we propose a new computational framework for characterizing
intra-tumor heterogeneity from VAFs of somatic mutations without using the copy-
neutral assumption. First, we describe a state-space formulation of the feature alloca-
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tion model [47]. This ensures that VAFs from as many genomic locations as possible
can be processed. Second, we describe an efficient SMC algorithm [38, 78] for the joint
estimation of all the hidden states and parameters of our state-space model, including
(i) a (Q+ 1)−ary matrix of subclonal total copy numbers, (ii) a (Q+ 1)−ary matrix
of subclonal variant copy numbers, (iii) a matrix of subclone proportions in the sam-
ples, and (iv) the number of distinct tumor subclones in the samples. Particularly,
we exploit the sequential construction of a (Q+ 1)− ary matrix with a known num-
ber of rows and an unknown number of columns, using the categorical Indian buffet
process (cIBP) [23]. In our state-space formulation, each row of the subclonal total
copy numbers and the subclonal variant numbers matrices is considered as the hidden
state of the system at a time step, and the proportion matrix and other parameters
are considered as the parameters of the system. In this way, the proposed algorithm
can process VAFs from any number of selected genomic locations. SMC [40, 79] is a
type of recursive filtering technique where measurements are processed one-by-one,
in a sequential fashion. As such, the posterior probability density function (PDF)
of the state is computed every time a measurement is observed. More precisely, the
posterior PDF of all the variables of interest are approximated with a set of properly
weighted samples, often referred to as particles [79]. This work is an extension to our
previous works on tumor heterogeneity with copy-neutral assumption [42, 80]. In the
former, the genotype matrix is modeled with a binary matrix, i.e., with or without
mutation at a genomic locus in a subclone [29]. In the latter, we looked at a more
complete case by modeling the genotype matrix with a ternary matrix which captures
the three possible genotypes in a diploid individual [75] (going forward, we will refer
to this as Method 1 ). The Indian buffet process (IBP) and the categorical IBP are
used to model the binary and the ternary processes, respectively.
Using simulated datasets, we extensively evaluate the proposed algorithm. With
the simulated datasets, we compare the proposed algorithm to BayClone2 [47], which
shares similar modeling assumptions and also estimates similar model parameters,
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PhyloWGS [32], and Method 1, a special case of the current work. The proposed
algorithm demonstrates better accuracy in estimating model parameters. Also, it
works better with small tumor samples (which mimics the real life situation where
few tumor samples are available), and has the capability to handle large genomic
locations.
The remainder of this chapter is organized as follows. In Section 3.2, we describe
the system model and problem formulation. In Section 3.3, we validate the proposed
algorithm with simulated data, as well as real data obtained from patients with high-
grade serous ovarian cancers. Finally, Section 3.4 has the discussion and conclusions
to the chapter.
In this chapter, we use the following notations:
1. p(·) and p(·|·) denote a PDF and a conditional PDF, respectively.
2. P (·) and P (·|·) denote a probability and a conditional probability mass function,
respectively.
3. binomial(n, p) denotes a binomial distribution with n number of trials and p
probability of success, and Γ(·) denotes the gamma function.
4. N (µ, σ2) denotes a Gaussian distribution with mean µ and variance σ2.
5. gam(α0, β0) denotes a gamma distribution with shape parameter α0 and rate
parameter β0.
6. beta(α1, β1) denotes a beta distribution with shape parameters α1 and β1.
7. Pois(λ) denotes a Poisson distribution with mean parameter λ.
8. Dir(α) denotes a Dirichlet distribution with a vector of concentration parame-
ters α.
9. xˆ denotes the estimate of variable x.
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3.2 System model and problem formulation
Assume that in an NGS experiment, S samples from the same patient across T
genomic locations have been sequenced. Two matrices D and V, each of dimension
T ×S, of read counts are observed. dts and vts are the elements in the tth row and the
sth column of D and V, respectively. At locus t in sample s, dts denotes the number
of reads that bear a variant sequence and vts denotes the total number of reads that
are mapped to the locus, t = 1, ..., T, s = 1, ..., S. We model the total read counts as
follows [47, 81]:





bts = lt0w0s +
C∑
c=1
ltcwcs, t = 1, ..., T, s = 1, ..., S,
(3.1)
where ψs, s = 1, ..., S, denotes the expected value of the number of reads in sample s
when the copy number of the sample is 2 (no CNV) and bts, t = 1, ..., T, s = 1, ..., S,
denotes the average copy number at locus t in sample s across the subclones. C
denotes an unknown number of distinct subclones in the samples, ltc ∈ {0, 1, ..., Q},
t = 1, ..., T , c = 1, ..., C, denotes the allele copy number at locus t in subclone c, Q
denotes the maximum allele copy number across all subclones in all the samples (its
value will be pre-specified) and wcs denotes the proportion of subclone c in sample s.
In (3.1),
∑C
c=1 ltcwcs describes the sample copy number as the weighted sum of the
subclonal copy number. Similarly, lt0w0s describes the expected copy number from a
background subclone, c = 0 which accounts for noise in the data. We assume that
lt0 = 2 for all t, i.e., there are no CNVs at any locus in the background subclone [47].
Conditional on vts, we model the variant read counts as follows [29, 47]:









where pts, t = 1, ..., T, s = 1, ..., S, denotes the success probability of observing a read
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with a variant sequence, ztc ∈ {0, ..., ltc}, t = 1, ..., T , c = 1, ..., C, denotes the number
of variant alleles among ltc allele copies at locus t in subclone c.
In (3.2),
∑C
c=1 ztcwcs shows that the variant allele copy number at a locus in a
sample is the weighted variant allele copy number across all the subclones in the
sample. Also, the term pzt0w0s describes the background subclone that accounts
for experimental noise (zt0 = 2 for all t), with p accounting for the noise that would
produce variant reads even in cases where no subclone has reads with variant sequence
[47].
From the data models in (3.1) and (3.2), we write the matrix of expected VAFs
or success probabilities as follows:
Pts =
(Z′ ·W)
(L′ ·W) , with Z
′ = [z0 Z] and L′ = [l0 L], (3.3)
where z0 = [pz10, ..., pzT0]
T , l0 = [l10, ..., lT0]
T , Z and L denote T × C (Q + 1) −
ary matrices of subclonal variant copy numbers and subclonal total copy numbers,
respectively, W denotes a (C+ 1)×S matrix of subclone proportions in the samples,
and each column in W sums to unity. The model in (3.3), our focus in this chapter,
accounts for the general case when it is assumed that the probed genomic locations
may be affected by CNVs. In the literature, a common scenario is the assumption
that the probed genomic locations are unaffected by CNVs, i.e., ltc = 2 in every locus




′ ·W [29, 74, 82]. Note that
A ·B denotes the multiplication of matrices A and B and A
B
denotes an element-wise
division of matrix A by matrix B.
Given the observed matrices of read counts, our goal is to perform a joint inference
on C, L, Z, W, p and ψ = [ψ1, ..., ψS], the model parameters that characterize intra-
tumor heterogeneity in the samples. To solve this problem, we do the following: (i)
we describe the system using a state-space model and (ii) we derive an efficient SMC
algorithm that sequentially estimates all the hidden states and the parameters in our
model.
CHAPTER 3. CHARACTERIZING INTRA-TUMOR HETEROGENEITY FROM
SOMATIC MUTATIONS WITHOUT COPY-NEUTRAL ASSUMPTION 42
3.2.1 State-space formulation
Our state-space framework takes advantage of the sequential construction of the two
(Q+ 1)− ary matrices L and Z in (3.3). At time t of the state-space model, the tth
row of L and Z are jointly viewed as the hidden state and the tth row of D and V are
jointly viewed as the observed measurement. Other unknown variables in (5.1) - (5.3),
including the proportion matrix W, are considered as the parameters of the state-
space model. Before explicitly writing our proposed state transition and measurement
models, we briefly describe cIBP, the sequential process for constructing a (Q+1)-ary
matrix with a known number of rows and an unknown number of columns. Given






























ltc|pic ∼ Discrete(pic) and pic ∼ BD
(α
C





where BD(·) denotes the beta-Dirichlet distribution [83], C+ denotes the number of
columns of L with non-zero entries, mcq =
∑T
t=1 I(ltc = q) denotes the number of
rows possessing value q ∈ {1, 2, ..., Q} in column c, and mc =
∑Q
q=1 mcq, as C → ∞,
[23] showed that the resulting distribution of L is the cIBP, i.e., L ∼ cIBPC(Q,α, β).
cIBP is a direct generalization of Indian buffet process (IBP) [84] and it is described
as follows. Imagine that in an Indian buffet restaurant, there is an infinite number
of dishes and assume that each dish comes with Q choices. For instance, assuming
that spice level of any particular choice of dish can be normal, mild, hot, and so on.
Now, we have T customers who arrive at the restaurant sequentially, one after the
other. The first customer walks into the restaurant and loads her plate from the first
c1 dishes, where c1 = Pois(α), and the spice level of the food in each of the dishes in
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the c1 plates is chosen with probability β/β
?, where β? = Qβ. The tth customers will
choose a particular dish with a specific choice according to the popularity of the dish,
i.e., choosing a dish c with a particular spice level with probability
(mtc
t






j=1 I(ljc = q), q ∈ {1, 2, ..., Q} denotes the number of customers before





the total number of customers before customer t who have tasted dish c. In addition,





new dishes, with the spice level of each of the chosen new
dishes determined with probability β/β∗.
Now, if we record the choices of each customer on each row of a matrix, where
each column corresponds to a dish on the buffet, then such a (Q+ 1)-ary matrix is a
draw from cIBPC(Q,α, β). The entire process is sequential because the choices made
by the tth customer are dependent only on the choices made by the t − 1 preceding
customers and not on the remaining T − t customers. In our case, the dishes in
the cIBP are the distinct subclones in the tumor samples and the selected genomic
locations are the customers.
3.2.1.1 State transition model
At time t, based on the sequential process of cIBP, the model for constructing the tth
row of matrix L, lt = [lt1, ..., ltCt ], is given as:
P (lt|Lt−1, α, β,Q). (3.5)
At any genomic location and in any tumor subclone, the number of alleles with
a variant sequence cannot be more than the total copy numbers, i.e., ztc ≤ ltc.
Thus, we consider the following model for constructing the tth row of matrix Z,
zt = [zt1, ..., ztCt ], given lt = [lt1, ..., ltCt ], the t
th row of matrix L. If ltc = 0, ztc = 0





, if ztc ∈ {0, 1, ..., ltc}
0, otherwise.
(3.6)
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(3.6) is a discrete uniform distribution [47]. Thus, with the cIBP and (3.6), we write
our proposed state transition model as:
P (lt, zt|Lt−1, α, β,Q), (3.7)
where Lt−1 denotes the previous t − 1 rows in matrix L. In the description of the
cIBP, we construct the matrix of subclonal copy numbers at time t, Lt from Lt−1.
During this process, if Lt has more non-zero columns than Lt−1 (i.e., Pois(α/t ) >
0), we need to add new rows to the proportion matrix W. To properly account for
the possible change in the dimension of W, we re-paremerize W by rewriting every
element in W as wcs = θcs/
∑C
c′=0 θc′s. This ensures that each column of W sums
to unity at every step of the construction process for L. In addition to the state
transition model in (3.7), using the random walk model, we create artificial dynamics
for the parameters in the proposed state-space model, i.e.,
φt ∼ p(φt|φt−1) = N (φt−1, σ2),
φt ∈ {p,ψ, θcs, c = 0, 1, ..., C, s = 1, ..., S}.
(3.8)
Thus, (3.7) and (3.8) describe the augmented state transition model for the system.
3.2.1.2 Measurement model
The tth row of the input read count matrices D and V, dt = [dt1, ..., dtS] and vt =
[vt1, ..., vtS], respectively, is the observed measurement at time t. From (3.1) and (3.2),
our proposed measurement model for the system is given as:
[dt,vt] ∼ P (dt,vt|lt, zt,W, p,ψ)




Pois(vts|lt, ψs,ws) · binomial(dts|vts, zt, lt,ws, p),
(3.9)
where ws is the s
th column of matrix W, ψs is the s
th element of ψ, and it is assumed
that [dt,vt] is conditionally independent of the previously observed measurements,
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Algorithm 3 Sample P (lt, zt|Lt−1, α, β,Q) using the categorical Indian buffet process
and the discrete uniform distribution in (3.6).
1: L← Lt−1
2: β∗ = βQ
3: if t = 1 then
4: Sample Cnewt ∼ Pois(α).
5: for c = 1, ..., Cnewt do









, ltc ∈ {1, ..., Q}










, ztc ∈ {0, ..., ltc}
8: end for
9: else
10: C+ ← Number of non-zero columns in Z
11: for c = 1, ..., C+ do
12: mcq ←
∑t−1















14: ltc ∼ Discrete([p0, p1, ..., pQ]), ltc ∈ {0, 1, ..., Q}
15: if lsc = 0 then
16: ztc|ltc ← 0
17: else










, ztc ∈ {0, ..., ltc}
19: end if
20: end for





22: for d = (C+ + 1), ..., (C+ + C
new
t ) do










, ltd ∈ {1, ..., Q}










; ztd ∈ {0, ..., ltd}
25: end for
26: end if
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Dt−1 and Vt−1, given the state [lt, zt]. Finally, (3.7) - (3.9) describe our proposed
state-space modeling framework for estimating the parameters of the feature alloca-
tion model from the observed VAFs of selected genomic locations.
3.2.2 Sequential Monte Carlo samplers
In the previous subsection, we presented our state-space formulation of the problem.
Next, we present a concise description of the SMC algorithm [38] to make inference,
jointly, on the state variables and the parameters of our proposed state-space model.
Assume we have a general dynamic system such that xt is the hidden state variable
and yt is the measurement variable at time t, p(x0) is the initial state model and we
have the full knowledge of the state transition and the measurement models ∀t ≥ 1.
In our proposed state-space model, xt is a mix of discrete variables (lt and zt) in (3.7)
and continuous variables φt, φt ∈ {pt,ψ, θtcs, c = 0, 1, ..., C, s = 1, ..., S} in (5.8), and
yt is the observed measurement [dt,vt] in (3.9). At each time t, given that we have
the sequence of observed measurements Yt = {y1,y2, ...,yt}, we want to estimate
the unobserved state sequence Xt = {x1,x2, ...,xt}. In other words, we want to
approximate the posterior distribution p(Xt|Yt) by samples (which we will refer to
as particles to avoid confusion with tumor samples) drawn from the distribution.
Obtaining such particles is not feasible in most models and such is the case in our
proposed model. However, the importance sampling theory allows us to obtain such
N weighted particles, {Xit}Ni=1, from an importance distribution, q(Xt|Yt), whose
support include the support of the original distribution, p(Xt|Yt).
In more detail, assume that at time t-1, the particles for approximating the se-
quence of states up to time t-1 are {Xit−1}Ni=1 and the weights at time t-1 are {wit−1}Ni=1.
At time t, the optimal importance distribution for obtaining new state particles
{xit−1}Ni=1 such that {Xit}Ni=1 = {xit,Xit−1}Ni=1, is p(xit|Xit−1,Yt), and the corresponding
unnormalized importance weights are computed as w˜it ∝ wit−1p(yt|Xit−1,Yt−1), i =
1, ..., N [85]. However, this special case is only possible if the densities p(yt|Xit,Yt−1)
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and p(xit|Xit−1,Yt−1) are conjugates, which implies that closed form solutions can
be obtained for the distributions p(xit|Xit−1,Yt) and p(yt|Xit−1,Yt−1). If no such
conjugacy exists, which is the case in our proposed state-space model, our solu-
tion, the most popular and equally efficient solution [86], is to set the importance
distribution to p(xit|Xit−1), and it is provided by (3.7) and (3.8) [43–46]. An algo-
rithm to sample from (3.7) is described in Algorithm 3. We can easily sample from
(3.8). For the weights, considering the assumed independence in our models, i.e.,
p(xit|Xit−1,Yt−1) = p(xit|Xit−1) and p(yt|Xit,Yt−1) = p(yt|xit), then the unnormalized






binomial(dts|vts, zit, lit,wis, pi),
(3.10)
and the weights {w˜it}Ni=1 are normalized to sum to unity. In the literature, such
implementation is commonly referred to as bootstrap filter [44].
Over time, the variance of the weights increases, a condition termed degeneracy
in the literature. To circumvent this, we perform resampling, at every time step,
because of the choice of our importance distribution [43–46]. Essentially, we discard
the ineffective particles and multiply the effective ones. The resampling procedure
[40] is as follows:
• Interpret each weight wit as the probability of obtaining the particle index i.
• Draw N particles from the discrete probability distribution and replace the old
particle set with this new one.
• Set all weights to the constant value wit = 1/N .
Finally, our proposed SMC algorithm for jointly estimating the states and the
parameters that characterize intra-tumor heterogeneity is presented in Algorithm 4.
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Algorithm 4 SMC algorithm for characterizing intra-tumor heterogeneity.
1: Input D, V
2: Initialize N particles {li0, zi0, pi0,Wi0,ψi0}Ni=1
3: for t = 1, ..., T do
4: for i = 1, ..., N do
5: Sample lit and z
i
t using Algorithm 3.
6: n1 ← number of columns in Lit−1
7: n2 ← length of lit
8: d← (n2 − n1)



















14: Sample Wit using (3.8)





18: Calculate w˜it using (3.10)
19: end for
20: Normalize the weights
21: Perform resampling
22: end for
23: Final particles and weights approximate the posterior estimates of L, Z and W.
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The algorithm is initialized by taking particles from the prior distributions of the
parameters as follows:
θi0s ∼ gam(a0, 1), s = 1, ..., S,
θics ∼ gam(a1, 1), s = 1, ..., S, c = 1, ..., C,
ψis ∼ gam(es1, es2), s = 1, ..., S, and pi ∼ beta(a00, b00).
(3.11)
Posterior estimates from the final particles are reported using the method described
in [47].
3.3 Results
3.3.1 Experiments on simulated datasets
To validate the proposed method and also perform comparison with other methods,
we generated multiple simulated datasets. Datasets are generated from different
combinations of the number of tumor samples S ∈ {3, 4, ..., 10}, number of tumor
subclones C ∈ {2, 3, 4} and the number of probed genomic locations T ∈ {20, 1000}.
Our data generation procedure, described next, is closely related to the approach
employed in [47].
To generate variant and total read counts for T genomic locations, S tumor sam-
ples and C subclones, the first step is to create the three matrices W, L and Z.
Thus, we sampled each column of W independently from a Dirichlet distribution,
i.e., ws = Dir([ao, a1, ..., aC ]), where a0 = 0.2 and ac ∈ {3, 8, 15, 20}. We let Q = 3
and sampled ltc from a discrete distribution such that P (ltc = 1), P (ltc = 2) and
P (ltc = 3) are 0.2, 0.5 and 0.3, respectively, for the general case, and 0, 1 and 0, re-
spectively, for the special case where the number of alleles at a locus is exactly 2.
Conditional on the value of ltc, ztc is obtained as we described in Section 3.2. The
second step is as follows: (i) from (3.1), we computed bts and sampled the total read
counts vt from the Poisson distribution, with ψs
iid∼ gam(5000, 2), (ii) from (3.2), we
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computed ats, pts and sampled the variant read counts dts independently from the
binomial distribution. We set p = 0.02.
The solution provided by the proposed algorithm is a blind deconvolution of the
observed VAFs into matrices L, Z and W. Hence, we have no idea of the correct
matching of the columns of the estimated matrix Lˆ to the columns of the true matrix




c=1 |lˆtc − ltc|
for all the possible permutations of the columns of L. The permutation with the
smallest e1 is used to rearrange the columns of Lˆ. Consequently, we considered
similar rearrangement for the columns and rows of Zˆ and Wˆ, respectively. For every
genomic location t and sample s, we computed pˆts. From pˆts and the true value pts,








|pˆts − pts|. (3.12)
In addition to evaluating the proposed algorithm, we used this metric to compare the
proposed method to BayClone2 and Method 1. Similar to the proposed method, it
should be noted that BayClone2 also estimates matrices L, Z and W. PhyloWGS is
compared to other methods via the error measure e2 = 1− rcC , where rc is the number
of correctly inferred subclones. To map the inferred genotypes from PhyloWGS to the
‘true’ genotype Z¯ (binarized Z: where all the inputs greater than 0 in Z are changed
to 1), we used the simple mapping method described in [74]. Specifically, genotype
mapping is done by comparing every column of the inferred genotype matrix to the
columns of Z¯ and pairing the columns with the smallest difference. In the pairing
process, we allowed up to 3 single nucleotide variant assignment error.
The results obtained from evaluating the proposed method with simulated data
are shown in Figures 3.1 and 3.2. We produced 20 simulated datasets for each combi-
nation of S ∈ {3, 4, ..., 10}, C ∈ {2, 3, 4} and T = 20. We ran the proposed algorithm
on each of the 20 datasets and computed the error of success probabilities ets de-
scribed in (5.12). In Figure 3.1, for each combination of S, C and T , we showed the
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Figure 3.1: Simulation results for the proposed method. Plot of the error
of success probabilities versus sample size S for different tumor subclones. Over 20
datasets, standard deviation is the vertical bar above and below the mean values.
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Figure 3.2: Histogram showing the difference between the estimated and the true
success probabilities for the proposed method for the dataset: T = 1000, S = 3 and
C = 2.
mean and standard deviation of ets over the 20 datasets. The mean value is at the
center and the standard deviation is the vertical bar above and below the mean value.
Also, we investigated the performance of the proposed algorithm for large number of
probed genomic locations. In particular, we considered T = 1000, C = 2 and S = 3.
For the dataset produced by this combination, we plotted, in Figure 3.2, a histogram
showing the fitting of the genomic locations in each sample under the model. With
tumor sample size of 3, the resulting histogram in Figure 3.2 shows a good fit under
the model and the error of success probabilities ets is 0.0421 for this dataset.
Figure 3.3 shows the results from comparing the proposed method on the datasets
in the general case, i.e., [P (ltc = 1)P (ltc = 2)P (ltc = 3)] = [0.2, 0.5, 0.3], with: (i)
the best case scenario where it is assumed that the L matrix is known and not
estimated, (ii) BayClone2, and (iii) Method 1. The particular case when L matrix
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Figure 3.3: Plot of error of success probabilities ets versus sample size S.
Simulation results comparing the proposed method to the best case scenario when
the L matrix is assumed known, BayClone2, and our previously proposed method on
the datasets with P (ltc = 1) = 0.2, P (ltc = 2) = 0.5, P (ltc = 3) = 0.3, T = 20, C = 2
and T ∈ {3, 4, ..., 10}.
is known provides the upper bound for performance, with smallest error of success
probabilities. The proposed method produced results that are closer to the best
performance, when compared to the two other methods. Further, Figure 3.4 shows
the results from comparing the proposed method on the datasets from the special case
with BayClone2 and Method 1. On these datasets, as expected, Method 1 produced
the best results, closely matched by the results from the proposed method. Lastly, we
generated 10 datasets with the combination T = 20, C = 4 and S = 10. We ran each
dataset on the proposed method, BayClone2 and PhyloWGS. The second and third
columns in Table 3.1 show the mean and standard deviation of error e2, respectively.
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Figure 3.4: Plot of error of success probabilities ets versus sample size S.
Simulation results comparing the proposed method to BayClone2, and our previously
proposed method on the datasets with P (ltc = 1) = 0, P (ltc = 2) = 1, P (ltc = 3) = 0,
T = 20, C = 2 and T ∈ {3, 4, ..., 10}.
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Table 3.1: Results comparing the performance of the proposed method, BayClone2
and PhyloWGS on dataset: T = 20, C = 4 and S = 10. Results show the average
and the standard deviation of the genotype error e2 across 10 datasets.
Method Average and standard deviation of e2 Average Cˆ
Proposed method 0.1500 [0.1288] 4
BayClone2 0.2800 [0.1331] 4
PhyloWGS 0.3400 [0.1318] 5.7
3.3.2 Experiments on real solid tumor
We evaluated the proposed method on a real dataset consisting of samples from
patients with high-grade serous ovarian cancers [87]. The authors performed bulk
deep sequencing on the samples and inferred the clonal genotypes and phylogenies
for each patient. The results of three patients (patients 2, 3, and 9) were further
validated by additional targeted single-cell sequencing. The sample sizes for these
patients are 10, 11 and 5, respectively. We applied the proposed method, as well as
PhyloWGS and BayClone2 with default or recommended hyper-parameter settings
to the read count data of somatic single nucleotide variants (SNVs) identified per
patient. Then, using the validated results for the three patients as benchmark, we
evaluated and compared the performance of different methods.
Our proposed method obtained the most consistent results with the benchmark in
terms of the inferred subclone numbers Table 3.2. Specifically, it predicted the correct
number of subclones for patient 2, while the error of prediction for the other two
patients was only two. By contrast, PhyloWGS resulted in a much larger number of
subclones in two of the three patients, consistent with the conclusions of recent study
that it sometimes produces an excessive number of subclones [74]. Specifically, many
of its inferred subclones (Supplementary Material in [88]) compose small proportions
in all samples, suggesting potential overfitting. As for BayClone2, it predicted ten
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Table 3.2: Numbers of subclones inferred by different methods for three real ovarian
cancer patients. The benchmark ones are obtained from the original study providing
the dataset.
Patient 2 Patient 3 Patient 9
Benchmark 7 8 4
Proposed method 7 6 6
PhyloWGS 8 30 26
BayClone2 10 10 10
subclones for all three patients, which, as we noted, is its maximum predictable
number.
We also evaluated methods by matching inferred with true subclones and compar-
ing the corresponding subclonal proportions. As a representative example, as it has
the largest sample size and number of sequenced loci among the data sets we con-
sidered, we selected patient 3 above. We assign pairs of inferred and true subclones
sharing the most similar genotypes as follows. We measure the pairwise subclonal
similarity by calculating the F1 score (harmonic average of precision and recall) be-
tween the two genotype vectors (1 if the mutation is present in the subclone, 0 if
not). Assuming that there are M inferred and N true subclones, there are M × N
pairwise similarities. The maximum of these M × N similarities is used to assign
the corresponding particular pair of inferred/true subclones. Then, having excluded
the above subclones, we take the maximum of the (M − 1) × (N − 1) similarities,
and we use it to assign another particular pair of inferred/true subclones, and so
on, until we have made min(M,N) such assignments of pairs. Next, we pair each
of the remaining max(M,N) − min(M,N) unpaired subclones with a hypothetical
subclone whose proportion is zero. Using the matched pairs, we calculated the pro-
portion error for each sample site by summing up the absolute differences between
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Figure 3.5: Sample-wise absolute errors of subclonal proportions evaluated against
the benchmark.
the inferred and true subclones for different methods (Figure 3.5). Except for two
samples (Adnx and Om1), the proposed method achieved the highest accuracy in all
the other nine samples. To perform an overall comparison, we applied paired t test
on the errors between different methods, and the results showed that the proposed
method outperformed both BayClone2 (P = 0.014) and PhyloWGS (P = 4.1× 10−4)
significantly.
3.4 Discussion
Intra-tumor heterogeneity describes a condition whereby different tumor cells in a
cancer patient show distinct mutational genotype profiles. NGS technology, such as
bulk tumor sequencing, has been widely employed in probing intra-tumor heterogene-
ity [13]. At sample level, this approach produces the total and variant read counts
that map to all the probed genomic locations (often summarized as VAFs). Proper
modeling and adequate analysis of the bulk tumor data can provide insight on ways
to prevent disease relapse and prognosis.
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In this chapter, we have provided a state-space framework to model the resulting
VAFs from bulk tumor sequencing. Our modeling approach takes VAFs of somatic
mutations as input and considers the effects of possible copy number variations oc-
curring at those mutation sites. We described an efficient sequential algorithm to
estimate both the total and variant copy numbers at every mutation loci. Our es-
timates also include the cellular proportions of every subclone in each of the tumor
samples. Unlike some previously proposed methods that only consider VAFs from
copy neutral regions of the genome [29, 31, 73, 74], our method assumes that the ob-
served VAFs could come from genome regions that are affected by CNVs. Also, since
the number of tumor subclones in the samples in generally unknown, our method
avoids specifying the number of subclones. In fact, the number of tumor subclones is
estimated alongside other model parameters in the proposed method.
On simulated datasets, one important consideration is when we have small number
of samples. The proposed method provided an accurate estimation of model param-
eters and equally a good fit under the proposed model, for all the 1000 genomic loci
in 3 samples. When compared to BayClone2, an algorithm with similar modeling
assumptions, the proposed method displayed significant improvements in the estima-
tion of model parameters (Figures 3.3 and 3.4), in addition to its ability to analyze
datasets with large genomic loci (as demonstrated with T = 1000). Also, based on
the estimated genotypes, we compared the proposed method with BayClone2 and
PhyloWGS (Table 3.2), and the proposed method showed a significant improvement
over the competing methods.
Similarly, we evaluated the proposed method using real genomic data from pa-
tients with high grade serous ovarian cancer. We used the results from the original
publication, which were validated by single-cell targeted sequencing, as ground truths
to compare against. Compared with BayClone2 and PhyloWGS, the results showed
that the proposed method achieved the highest accuracy for inferring tumor hetero-
geneity.
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Lastly, the modeling framework and the algorithm described in this chapter allow
VAFs from any number of probed genomic loci (consistent with whole genome and
whole exome sequencing) to be modeled and analyzed in a computationally efficient
manner. Although we noticed that particle size N = 500 is sufficient for the experi-
ments performed in this chapter, it is possible to improve on the accuracy of model
estimates if more particles are used.
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Part II
Modeling gene expression data
CHAPTER 4. REVERSE ENGINEERING GENE REGULATORY NETWORKS




measurement with missing values
4.1 Introduction
Gene regulation happens to be one of the most important processes that take place in
living cells [89, 90]. For instance, it includes controls over the transcription of messen-
ger RNA (mRNA) and the eventual translation of mRNA into protein via gene regu-
latory networks (GRNs). A detailed network may depict various inter-dependencies
among genes where nodes of the network represent the genes and the edges correspond
to interactions among the genes [91]. The strength of these interactions represents
the extent to which a gene is affected by other genes in the network. For instance,
some of the genes encode specific proteins, known as the transcription factors that can
bind deoxyribonucleic acid (DNA) as part of a complex or independently and regulate
their rate of transcription [92, 93]. Binding of the DNA by the transcription factors
may, in some occasions, include genes that encode for other transcription factors and
also genes that encode proteins for other functions. Hence, this results in a complex
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level of interaction among the genes in the cell. Among others, understanding the
complex intracellular network in a human cell may lead to the identification of dis-
eased genes, drug targets, and biomarkers for complex diseases [94]. Thus, identifying
the structure of GRNs has become a major focus in the systems approach to biology
[95–98].
The generation of high throughput time series measurement of transcript levels
(e.g., via microarray experiments) has become an increasingly powerful tool for in-
vestigating complex biological processes and a useful resource for GRN inference [99].
Modeling of the gene networks with gene expression data can be loosely categorized
into static and dynamic models. A static approach to modeling gene expressions
makes use of the following properties: correlation, statistical independence for clus-
tering, and mutual information [100, 101]. Particularly, the clustering approach has
gained significant popularity [102, 103]. On the other hand, the dynamic modeling
of GRNs from time series data has also received considerable interest. For instance,
Boolean network models quantize the empirical gene expression data into binary
values [104] and view the network structures as constraints. Further, via the estima-
tion of the parameters in S-systems, a kind of nonlinear mathematical models based
on power law, few authors like [105, 106] have performed the reverse engineering of
GRNs. Probabilistic Boolean network models are an extension to the Boolean net-
work models which incorporate the inherent stochasticity of gene expression and the
uncertainties introduced by the measurement noise [107]. Also, dynamic Bayesian
networks (DBNs) have been proposed to model the time series gene expression data
[108, 109] because DBNs can model stochasticity and handle noisy/hidden variables.
The state-space approach, an extension of the DBNs, is a popular technique to
model the GRNs [110, 111], where the hidden state of the network can be estimated
by Gaussian approximation (GA) filters. The conventional Kalman filter, being op-
timal for a linear Gaussian system [112], requires some modifications to be able to
cope with the nonlinearity of the activation function that regulates the gene activity
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profile. For instance, the extended Kalman filter (EKF) uses the first-order terms of
the Taylor’s series expansion [113] to linearize the nonlinear functions in the model.
The EKF only calculates the posterior densities accurately to the first order with
all higher moments truncated. A different paradigm of the GA filtering approach is
the point-based filtering technique, which involves numerically integrating nonlinear
functions by using a set of deterministic points. This approach lowers the compu-
tational complexity when compared to the Monte Carlo numerical integration which
relies on randomly generated points, since it requires much less number of points with
the same accuracy.
However, in reality, gene expression time series data may not contain sufficient
quantity of data in the appropriate format for the inference of GRNs because of the
missing data points [114]. For example, in microarray measurement of gene expres-
sion, errors such as insufficient resolution and image corruption or simply due to dust
or scratches on the slide of a microarray chip may occur in the experimental process
which lead to corruption or absence of some expression measurements. In the engi-
neering literature, similar problems are inherent in networked control systems (NCS)
and sensor networks where packet dropouts and time delays are an unavoidable phe-
nomenon during data transmission [115]. Classical methods fail to solve the filtering
and estimation problems for such cases with delays and missing data and cannot
accurately infer the underlying network structure.
In this chapter, we present a class of GA filters for inferring GRN from data with
missing measurement values, which can be modeled in the same unifying framework
as in the case of state estimation from one-step or two-step randomly delayed mea-
surements [116]. A general framework is presented through augmenting the state
variables and with Gaussian assumptions on the posterior state and missing mea-
surement. To make GRN inference from measurements that contain missing data,
we describe the network by a nonlinear model and a measurement model that in-
corporates the missing data. The inferred parameter set can be used to identify the
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underlying regulatory network structure.
In the literature, several point-based Gaussian approximation (PBGA) filters have
been used for solving the GRN inference problem from DNA microarray gene expres-
sion data and genome-wide knockout fitness data [117, 118]; however, there is no
solution that outperforms all other counterparts. Thus, one has to pick the filter
balancing the estimation performance, implementation complexity, and filter stabil-
ity. Prominent among the PBGA filters are the cubature Kalman filter (CKF) that
makes use of the third-degree cubature rule [119], the unscented Kalman filter (UKF)
that makes use of the unscented transformation [118, 120], and the central difference
Kalman filter (CDKF) that makes use of the difference rule.
The remainder of this chapter is organized as follows. In Section 4.2, we describe
the system model, problem formulation and the corresponding GA filter. In Sec-
tion 4.3, we investigate the performance of the proposed algorithm on a synthetic
network and a diverse set of in silico networks released as a part of the DREAM
project, from which observations can be made for benchmarking purposes [121, 122].
In addition, we present results on a real data obtained from the IRMA network of
yeast Saccaromyces cerevisiae [123]. Section 4.4 has the discussion and finally, Sec-
tion 4.5 concludes the chapter.
In this chapter, we use the following notations:
1. N (x;µ,Σ) denotes the Gaussian probability density function with mean µ and
covariance Σ.
2. Eg{·|µ,Σ} denotes the Gaussian integral with respect to N (x;µ,Σ).
3. xˆ represents the estimate of variable x, x˜ = x− xˆ is the estimation error, and
E[·] denotes the expectation operation.
4. X−1 and XT represent the inverse and transpose of matrix X, respectively, and
In denotes the n-dimensional identity matrix.
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4.2 Methods
4.2.1 Problem formulation and system model
Gene regulatory networks can be modeled as either static or dynamic systems. In this
chapter, the state-space model is used which is an instance of the dynamic modeling
and can effectively cope with time variations in the gene expression data. Consider
a GRN consisting of N genes. Let gi,k, i = 1, ..., N, k = 1, ..., K denote the gene
expression level for the ith gene at time step k where K is the total number of data
points available. Here, “time” is a discrete index enumerating data points sampled at
regular intervals. A well-adopted nonlinear model [113, 118] that captures the gene
interactions and the evolution of gene expression values effectively is the discrete-time







bijf(gj,k−1, µj) + I0i + ek−1,i i, j = 1, ..., N, k = 1, ..., K,
(4.1)
where aij is the linear regulatory coefficient from gene j to gene i, bij is the nonlinear
regulatory coefficient from gene j to gene i, N is the total number of genes in the





with µ being a parameter to be identified and I0i being the external bias on the ith
gene. The noise vector ek = [ek,1, ..., ek,N ]
T is Gausssian distributed with zero mean
and covariance matrix Q
′
k, for k = 1, ..., K.
The goal of inference is to estimate the parameters (coefficients) of the model in
(4.1), which form the basis of the GRN. To that end, the state vector is concatenated
with the model parameters to form augmented state vector as follows. Denote A =
[a11, ..., a1N , a21, ..., a2N , aN1, ..., aNN ]
T , B = [b11, ..., b1N , b21, ..., b2N , bN1, ..., bNN ]
T , µ =
[µ1, ..., µN ]
T and I0 = [I01, ..., I0N ]
T and we denote the expression level for all genes
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at time step k by gk = [gi,k, ..., gN,k]




T ,BT ,µT , IT0 ]
T ∈ R(2N2+3N). (4.3)
The augmented version of the state transition equations include (5.1) and the
following:
aij,k = aij,k−1, bij,k = bij,k−1,
µi,k = µi,k−1, I0i,k = I0i,k−1, i, j = 1, ..., N.
(4.4)
Succinctly, the state transition of the dynamic model is written as:
xk = f(xk−1) + wk−1, (4.5)
where f(·) is the nonlinear function associated with (5.2) and (5.4);
wk = [ek,1, ..., ek,N , 0, ..., 0]
T is the augmented noise vector with covariance matrix
Qk = diag([Q
′
k 02N+2N2 ]), where 0m denotes an m×m all-zero matrix.
The measured gene expression levels can be modeled as:
zk = h(xk) + vk, (4.6)
where zk is the output data from the experiments at time k, h(xk) = gk and vk ∈ RN
is Gaussian distributed noise with zero mean and covariance matrix Rk ∈ RN×N .
Now, we consider the case that some measurement outputs zk, are missing and
the estimation is made from the available measurements, yk. We assume that z1 is
available. At time k = 2, if the measurement output is missing, estimation is done
with z1 and at any time instant k ≥ 3, maximum of two consecutive time points may
be missing. In summary, if zk is missing estimation is done with zk−1 and if zk−1
is unavailable, estimation is done with zk−2. Thus, the measurement output at each




γdkzk−d (k ≥ 1) (4.7)
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with
γ0k = 1− ςk, γ1k = ςk(1− ςk−1), and γ2k = ςkςk−1, (4.8)
where ς1 = 0, ςk is a Bernoulli random variable with probability p(ςk = 1)(k ≥ 2) = q.
Moreover, it is assumed that x0, {wk, k ≥ 0}, {vk, k ≥ 1}, and {ςk, k ≥ 2} are
mutually independent. Denote pdk(d = 0, 1, 2) as the probabilities that measurements
zk, zk−1, and zk−2 are used at time k. Then, we have:
p0k =
∆ p(γ0k = 1) = E[γ0k] = 1− q,
p1k =
∆ p(γ1k = 1) = E[γ1k] = q(1− q),
p2k =
∆ p(γ2k = 1) = E[γ2k] = q2.
(4.9)
Finally, (4.5)-(4.8) describe the dynamic model we propose for inferring GRNs
with one-step or two-step missing measurements.
To estimate the GRN based on (4.5)-(4.8), we solve the optimal filtering problem
by finding the estimator E[xk|Yk], where Yk =∆ (y1, ...,yk). With the Bayes rule,
the conditional probability density function (PDF) p(xk|Yk), and subsequently its
first two moments, i.e., xˆk|k = E[xk|Yk] and Pxxk|k = E[x˜k|kx˜Tk|k|Yk], are recursively
obtained through estimating the posterior predictive PDF of the state p(xk|Yk−1),
and the measurement p(yk|Yk−1), where x˜ = x − xˆ is the estimation error. For the
purpose of filtering, we will make use of the following Gaussian assumptions:
1. The one-step posterior predictive PDF of the state xk conditioned on Yk−1 is
Gaussian, i.e.,
p(xk|Yk−1) = N (xk; xˆk|k−1,Pxxk|k−1), (4.10)
where
xˆk|k−1 = E[xk|Yk−1], Pxxk|k−1 = E[x˜k|k−1x˜Tk|k−1|Yk−1] (4.11)
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2. The one-step posterior predictive PDF of yk conditioned on Yk−1 is Gaussian,
i.e.,
p(yk|Yk−1) = N (yk; yˆk|k−1,Pyyk|k−1), (4.12)
where
yˆk|k−1 = E[yk|Yk−1], Pyyk|k−1 = E[y˜k|k−1y˜Tk|k−1|Yk−1]. (4.13)
4.2.2 Gaussian approximation filters with missing measure-
ments
In this section, we briefly present the general GA filtering framework for the PBGA
filters with one-step or two-step missing measurements for the state-space dynamic
model. In the Supplementary Material in [41], we detail its derivation, we review dif-
ferent numerical techniques for approximating multidimensional Gaussian weighted
integrals that involve nonlinear transformation of random vectors, and we present the
algorithm that implements the UKF version of the filter. Given all the measurements
up to the present time in the system described in (4.5) and (4.6), the standard Gaus-
sian filter operates by updating only the posterior PDF of the state, i.e., p(xk|Yk)
[126]. However, in the case that the measurements are randomly delayed (or missing)
by one or two sampling times as described in (4.7), apart from p(xk|Yk), the poste-
rior PDFs p(vk|Yk), p(xk−1|Yk), and p(vk−1|Yk) also must be updated. Specifically,




γdk [h(xk−d) + vk−d] (k ≥ 3). (4.14)
Substituting (4.14) into (4.13) incorporates the delayed measurement in the GA
filter, such that yˆk|k−1 and P
yy
k|k−1 depend on the estimates xˆk−d and vˆk−d, d = 0, 1, 2.
By the Gaussian assumptions, it boils down to computing the first two moments of
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p(vk−1|Yk−1), p(xk−2|Yk−1), and p(vk−2|Yk−1). This is achieved through augmenting








Given the Gaussian approximations to p(xk|Yk) , p(vk|Yk), p(xk−1|Yk), and
p(vk−1|Yk), the posterior PDFs p(xak−1|Yk), p(xak|Yk), and p(Xk|Yk) of the aug-
mented states xak−1, x
a
k, and Xk are approximated as Gaussian respectively as:
p(xak−1|Yk) = N (xak−1; xˆak−1|k,Paak−1|k),
p(xak|Yk) = N (xak; xˆak|k,Paak|k),
































with Paak−1,k|k = E[x˜ak−1|k(x˜ak|k)T |Yk].
(4.19)
As with the general GA filtering , the filtering procedure consists of the state
update and measurement update.
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4.2.2.1 State update










with Paak−2,k−1|k−1 = E[x˜ak−2|k−1(x˜ak−1|k−1)T |Yk−1],
(4.20)















where xˆak−1|k−1 and P
aa





Pxxk|k−1 = Eg{f(xk−1)fTk−1(xk−1)|Xˆk−1|k−1,PXXk−1|k−1} − xˆk|k−1xˆk|k−1 + Qk−1,
Paxk−1,k|k−1 = Eg{xak−1fTk−1(xk−1)|Xˆk−1|k−1,PXXk−1|k−1} − xˆak−1|k−1xˆk|k−1.
(4.22)
For the detailed derivations, see the Supplementary Material in [41].
4.2.2.2 Measurement update
After obtaining the approximation to the predictive PDF p(Xk|Yk−1), the Gaussian
approximation of the augmented state posterior PDF p(Xk|Yk) is obtained by the
Kalman filter equations:
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For d = 0:
zˆk|k−1 = Eg{h(xk)|Xˆk|k−1,PXXk|k−1},
Pzzk|k−1 = Eg{h(xk)hTk (xk)|Xˆk|k−1,PXXk|k−1} − zˆk|k−1zˆTk|k−1 + Rk,
PXzk|k−1 = Eg{Xk(hk(xk) + vk)T |Xˆk|k−1,PXXk|k−1} − Xˆk|k−1zˆTk|k−1,
(4.25)
for d = 1:
zˆk−1|k−1 = Eg{h(xk−1 + vk−1)|Xˆk|k−1,PXXk|k−1},
Pzzk−1|k−1 = Eg{(h(xk−1) + vk−1)(h(xk−1) + vk−1)T |Xˆk|k−1,PXXk|k−1} − zˆk−1|k−1zˆTk−1|k−1,
PXzk,k−1|k−1 = Eg{Xk(h(xk−1) + vk−1)T |Xˆk|k−1,PXXk|k−1} − Xˆk|k−1zˆTk|k−1,
(4.26)
for d = 2:
zˆk−2|k−1 = Eg{h(xk−2 + vk−2)|Xˆk|k−1,PXXk|k−1},








The filtering estimate xˆk|k and covariance Pxxk|k of the system state are obtained
from Xˆk|k and PXXk|k respectively. (See the Supplementary Material in [41]).
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However, the Gaussian weighted integrals in (4.22) and (4.25)-(4.27) contain non-
linear functions which render the analytical calculation infeasible and the algorithm
becomes intractable. To deal with this, we employ the point-based numerical inte-
gration techniques, which is presented in the Supplementary Material in [41].
4.3 Results
We assess the proposed algorithm using both synthetic data and real data. Gold stan-
dards or the ground-truths are provided for both categories of data and the inferred
networks are “benchmarked” against the gold standards. Benchmarking is done by
counting the number of links correctly predicted by the algorithm (true positives,
TP), the number of incorrectly predicted links (false positives, FP), the number of
true links missed in the inferred network (false negatives, FN), and the number of
correctly identified non-existing links (true negatives, TN). Thus, the following per-
formance metrics will be defined accordingly: true positive rate or recall also known
as the sensitivity (TPR = TP/(TP+FN)), positive predictive value or precision (PPV
= TP/(TP+FP)), and false positive rate (FPR = FP/(FP+TN), where specificity =
1-FPR). All the metrics are computed for different thresholds and the area under the
receiver operating characteristic (AUROC) curve and the area under the precision-
recall (AUPR) curve are estimated to illustrate the overall inference performance of
the algorithms. As the inference result comprises of the estimates of both the linear
and nonlinear regulatory coefficients among the genes, if at least one of the regulatory
coefficients between any two genes is recovered, the link is designated as TP.
In addition, y1 = z1; at time k = 2 the measurement output can be missing by
one-step; and at any time instant k ≥ 3 it can be missing by one-step or two-step.
With the prior knowledge of the number of missing data points to be replaced in
the experimental output, an estimate of the value of q, the success probability of the
Bernoulli variable ςk can be made. Specifically, if the number of missing data points
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is less than 20% of the total number of data points, a q value chosen in the interval
[0.05, 0.2] is a good choice. In our experiments, q = 0.1, so that the probability
that zk is used in the estimation is p
0
k = 0.9, the probability that zk−1 is used in
the estimation p1k = 0.09, and the probability that zk−2 is used in the estimation is
p2k = 0.01. In the remainder of this chapter, we denote the datasets that have no
missing values as the complete measurements (CM) and we denote the datasets with
missing but replaced data points as the missing measurements (MM). The MM is
created in the following manner: at time k, if zk is missing and zk−1 is available, we
replace zk with zk−1; otherwise, we replace zk with zk−2, as there can be maximum
of two consecutive missing data points in the measurement.
4.3.1 Synthetic network
The synthetic network in Figure 5.1(a) is assumed to have both linear and nonlinear
connections. The dynamics of the network are based on the model given by (4.5)-
(4.8), with arrows denoting the direction of regulatory interactions. The parameters
of the network, i.e., the linear connection coefficients (LCC) and the nonlinear con-
nection coefficients (NCC), are given in the second column in Table ?? with the NCC
in parentheses. The underlying zero-mean Gaussian process noise has a covariance
matrix Qk = 0.004I, and the zero-mean Gaussian measurement noise has a covari-
ance matrix Rk = 0.001I, k = 1, ...,M . Time series data are generated for a total of
M = 50 time points. To quantify the results more rigorously, we set the noise thresh-
old at 40% of the maximal variation for linear and nonlinear coefficients such that
if an inferred link is less than this threshold, it is considered noise and subsequently
filtered off. In the end, we come up with sparse networks and the TPR and PPV
metrics are calculated for the networks.
First, we supplied the CM data to the UKF algorithm. The inferred model param-
eters are shown in the third column in Table 4.1, with the NCC in parentheses. The
corresponding network is displayed in Figure 4.1(b) where the solid edges indicate the
CHAPTER 4. REVERSE ENGINEERING GENE REGULATORY NETWORKS





















Figure 4.1: Synthetic network. Solid black edges denote the linear connections,
dashed blue edges denote the nonlinear connections, and the dotted red arrows indi-
cate false positives. (a) Gold standard for the synthetic network. (b) Inferred linear
and nonlinear connections by the UKF with CM. (c) Inferred linear and nonlinear
connections by the UKF with MM. (d) Inferred linear and nonlinear connections with
the proposed UKFRMM with MM
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Table 4.1: Network parameters for the synthetic network.
Edge LCC and NCC UKF with CM UKF with MM UKFMM with MM
(1,1) 0.5 (0.4) — (0.5880) — — 0.7313 —
(3,1) 0.5 (0.4) 0.3837 (0.4391) 0.7357 (0.5043) 0.4079 (0.4223)
(3,2) 0.5 (0.4) 0.7380 (0.4390) — — 0.7380 (0.4192)
(3,5) 0.5 (0.4) 0.6098 (0.4391) 0.6623 (0.5043) 0.8285 (0.4354)
(4,3) 0.5 (0.4) 0.7257 (0.3059) 0.3953 (0.2123) 0.7256 (0.3235)
(5,2) 0.5 (0.4) — (0.3837) — — — (0.3235)
(5,4) 0.5 (0.4) 0.6677 (0.3839) 0.5813 (0.3706) 0.7850 (0.3464)
(4,4) — — — — — (0.8417) — —
(5,1) — — — — — (0.5916) — —
(5,5) — — — — — (0.3705) — —
(1,5) — — — — — — 0.5722 —
Parameters of the synthetic network and the networks inferred by the UKF
algorithm with CM, UKF algorithm with MM, and the proposed UKFMM with
MM. The bold edges do not exist in the original network. The false negatives are
represented by (non-bold) dashes, and false positives are given in bold numbers.
Table 4.2: Average TPR and PPV for the synthetic network (standard deviations are
shown in parentheses).
UKF with CM UKF with MM UKFMM with MM
TPR 1.00 0.48 (0.035) 0.91 (0.017)
PPV 1.00 0.53 (0.028) 0.86 (0.013)
inferred linear connections and the dashed edges indicate the inferred nonlinear con-
nections. Next, we create the MM data by removing data points 10, 11, 25, 35, 36, and
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40 from the time series data; the removed data points are then replaced accordingly.
To investigate the impact of missing data points on the performance of inference
algorithms, we supplied the MM data to the UKF algorithm. The inferred model
parameters are shown in the fourth column in Table 4.1 and the network structure
is shown in Figure 4.1(c). The black dotted arrows indicate the false positives, i.e.,
incorrectly predicted links. Finally, using the same MM data we tested the proposed
UKF with one-step or two-step missing measurements (UKFMM). The inferred model
parameters are shown in the fifth column in Table 4.1 and the inferred network is dis-
played in Figure 4.1(d). It is observed that the missing data points have great impact
on the performance of the UKF algorithm; whereas the proposed UKFMM algorithm
can deal with the missing data effectively by dis- playing a robust performance which
is in fact at par with the performance of the UKF with CM. To average out the influ-
ence of random data deletion, we run the experiment 1000 times, where at each run,
we randomly deleted up to five data points, with maximum of two consecutive data
points, and replaced the deleted data points in similar manner as described above.
For all the runs, we record the TPR and the PPV, and the average TPR and PPV
with their standard deviations (shown in parentheses) are shown in Table 4.2.
4.3.2 DREAM4 in silico gene regulatory networks
In order to assess the performance of GRN inference algorithms, several in silico gene
networks have been produced as the benchmarking data sets, specifically, the DREAM
in silico gene networks [127–129]. We made use of the 10-gene networks by the
DREAM4 challenge to test the efficacy of the proposed algorithm. All networks and
data were generated with version 2.0 of GeneNetWeaver (GNW) [130]. In total, there
are five separate networks, each with 10 genes, whose topologies were extracted from
the known GRNs in Escherichia coli and Saccharomyces cerevisiae. The time series
measurements were generated using parametrized stochastic differential equations
(SDEs), with observations uniformly sampled (21 time points, single replicate) under
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Table 4.3: AUROC and AUPR curves for the DREAM4 networks.
UKF with CM UKF with MM GP4GRN with CM GP4GRN with MM UKFMM with MM
N1 [0.63] [0.42] [0.44(0.024)][0.24(0.020)] [0.66] [0.42] [0.42(0.027)][0.29(0.021)] [0.61(0.015)][0.42(0.008)]
N2 [0.67] [0.49] [0.48(0.018)][0.26(0.017)] [0.69] [0.44] [0.44(0.015)][0.28(0.018)] [0.64(0.013)][0.44(0.011)]
N3 [0.72] [0.50] [0.45(0.020)][0.30(0.012)] [0.70] [0.47] [0.50(0.022)][0.33(0.016)] [0.72(0.021)][0.53(0.012)]
N4 [0.75] [0.52] [0.56(0.019)][0.28(0.011)] [0.62] [0.35] [0.36(0.031)][0.25(0.027)] [0.72(0.009)][0.50(0.010)]
N5 [0.81] [0.44] [0.53(0.021)][0.26(0.019)] [0.86] [0.65] [0.55(0.022)][0.40(0.019)] [0.80(0.012)][0.42(0.014)]
Column 1 shows the network number. In columns 3, 5, and 6, average AUROC and
average AUPR are presented in the square brackets and the standard deviations are
in parentheses.
five different perturbations, for a total of 105 observations per gene. The inference is
performed by using all the perturbations. Self-interaction/autoregulatory edges were
not expected in the predictions and were subsequently removed. Since the number of
possible edges in an N -gene network without autoregulatory interactions is N(N−1),
the length of a complete list of predictions is 90 edges for a network of size 10 [121, 122].
We first test the UKF algorithm on the five 10-gene network data sets (CM) and
the result is shown in column 2 in Table 4.3. To average out the influence of random
data deletion, we ran 1000 experiments where at each run, we created the MM by
randomly deleting up to five data points, with maximum of two consecutive data
points, and replaced the deleted data points accordingly. For each run, we fed both
the UKF and the proposed UKFMM algorithms with the MM and we record the
average AUROC and AUPR scores for each of the five networks, where the empirical
averages and standard deviations over 1000 experiments are shown in columns three
and six, respectively in Table 4.3. Again, it is seen from Table 4.3 that the proposed
UKFMM algorithm is robust against the miss- ing data conditions where it can infer
the network as accurately as the UKF algorithm that uses the CM.
We also compared our algorithm against a relevant computational method de-
signed for the GRN network inference, i.e., [131], which is based on the use of Bayesian
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analysis with ordinary differential equations (ODEs) and non-parametric Gaussian
process, an algorithm referred to as GP4GRN. The inference result of GP4GRN with
CM is shown in the fourth column in Table 4.3. Similarly, we tested GP4GRN with the
MM where we ran 1000 experiments. At each run, we created the MM by randomly
deleting up to five data points with maximum of two consecutive data points and
replaced the deleted data points accordingly. The averages and standard deviations
of AUROC and AUPR are obtained and the corresponding results are summarized
in the fifth column in Table 4.3. We conclude that the GP4GRN method has com-
parable performance to the UKF in all data sets, and similarly it is outperformed by
the proposed UKFMM algorithm under missing data conditions.
4.3.3 Saccharomyces cerevisiae IRMA network
Saccharomyces cerevisiae GAL network in yeast is one of the most prominent model
systems due to its importance for the studies of eukaryotic regulation and relatively
self- contained nature [132–135]. A synthetic GRN that contains 5 genes has pre-
viously been constructed in the budding yeast [123]. In the well studied network,
popularly referred to as in vivo reverse engineering and modeling assessment (IRMA)
network, each of the genes regulate at least one other gene in the network. Expres-
sion within the network is activated in the presence of galactose and then switched
to glucose to obtain the switch-off data which represents the expressive samples at
21 time points. The switch-on data consists of 16 sample points and is obtained by
growing the cells in a glucose medium and then changing to galactose.
The true interactions is shown in Figure 4.2(a). The real biological data is first
supplied to the UKF algorithm and the inferred network is shown in Figure 4.2(b).
As standard, some data points are randomly discarded from the input and they are
replaced accordingly to generate the MM. The UKF and the proposed algorithm
UKFMM are tested on the generated data set (MM) and the inferred networks are
shown in Figure 4.2(c), (d), respectively, and the corresponding results are summa-
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Figure 4.2: Yeast network. Solid black edges denote the combined linear and
nonlinear connections, the true positives. The dotted red edge is a false positive. (a)
Gold standard/ground-truth for the yeast network. (b) Inferred yeast network by the
UKF with CM. (c) Inferred yeast network by the UKF with MM. (d) Inferred yeast
network by the proposed UKFRMM with MM.
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Table 4.4: AUROC and AUPR curve for the yeast networks.
UKF with CM UKF with MM GP4GRN with CM GP4GRN with MM Proposed UKFMM
AUROC curve 0.70 0.42 0.76 0.49 0.68
AUPR curve 0.46 0.34 0.57 0.38 0.46
rized in Table 4.4. Again, on the missing data condition, the proposed algorithm
shows a better performance compared to the UKF. In addition, we also test the
GP4GRN algorithm with both CM and MM and the results are presented in the
fourth and fifth columns in Table 4.4, which further affirms the impact of missing
measurements in the GRN inference methods and the relative robustness of the pro-
posed UKFMM algorithm.
4.4 Discussion
This work presents a novel algorithm for GRN inference from time-series gene ex-
pression data with one-step or two-step missing measurements. Gene regulation is
assumed to follow a nonlinear state evolution model described in (4.1). The param-
eters of the model, which are assumed to be the regulatory coefficients between the
genes, are estimated with a modified unscented Kalman filtering algorithm. We con-
sidered the experimental scenarios that lead to total loss of expression values for all
genes at a particular time point or few successive time points which may significantly
diminish the performance of GRN inference algorithms. In the proposed algorithm,
the state vector which is the gene expression at each time point in (4.1) is concate-
nated with the model parameters and an augmented state vector in (4.3) is defined for
the joint estimation of gene expression values and system parameters. We consider
the possibility that each real measurement is randomly missing and the estimation
is made from the available measurements. The use of the UKF, an instance of the
PBGA filters, for the state and parameter estimation renders the algorithm computa-
tionally efficient and capable of working offline or online (when all the measurements
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are readily available, or they become available successively, respectively). The pro-
posed algorithm is tested on both synthetic and real biological data to evaluate the
efficacy of the predictions. From the series of results obtained for both synthetic data
and the real biological data, we conclude that the gene network structure can be
inferred from time series data with missing values.
In this chapter, we have applied the proposed algorithm to the time series data
generated from the DNA microarray because to our best of knowledge, DNA microar-
ray is still of interest in transcriptome profiling due to its reduced cost and widespread
use as compared to the RNA-seq. In addition, it has been shown that there is there is
high correlation between the gene expression profiles generated between the DNA mi-
croarray and RNA-seq [136, 137]. Hence, the proposed method can easily be extended
to time series gene expression data from RNA-seq.
In general, this work addresses the possibility of having one-step or two-step miss-
ing expression values by considering them as the delayed observations of the full set
of genes. Future work will focus on the inference of the structure of a (potentially
larger) network by incorporating a general s-step missing values for s-consecutive time
points, which may address more complex missing data scenarios.
4.5 Conclusions
Time series gene expression data be modeled with state-space model and the model
parameters can be estimated using different GA filters. Unfortunately, there are
situations which result in loss of expression values for all genes at a particular time
point or few successive time points. In this case, conventional filtering approach fails
to correctly estimate the model parameters, which are used to elucidate the underlying
GRN. We have proposed PBGA filters that treat the missing measurement values as
a set of delayed measurements and demonstrated that the modified filter can estimate
the model parameters, with missing measurements, as accurate as the conventional
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filter with no missing measurements.
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Chapter 5
A sequential Monte Carlo approach
to gene expression deconvolution
5.1 Introduction
Gene expression measurement technologies, for example, deoxyribonucleic acid (DNA)
microarray, have made it possible to conduct simultaneous expression measurements
from thousands of genes on a genome-wide scale [20, 138–140]. Gene expression data
obtained from pure samples, comprising of a single cell type, can be analyzed to yield
a significant amount of information. For instance, measuring gene expression levels
in different conditions may prove useful in medical diagnosis, treatment prescription,
drug design [141, 142] and most importantly in the identification of genes that are dif-
ferentially expressed between groups of samples [143], such as tumor versus non-tumor
tissues [144].
However, in heterogeneous samples, where more than one cell types are present,
drawing any reasonable conclusion is a difficult task because each of the cell types in
the sample will contribute differently to the measured expression of a given gene [145].
In some cases, manual methods such as laser microdissection (LMD) [22] and flow
cytometry [146] are employed to isolate cells of interest from the complex mixtures. In
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spite of that, there are some limitations in using these techniques. For instance, they
are very expensive and often come with low cell throughput rate [147–149], resulting
in a drastic reduction in the yield of biological contents.
In the literature, different computational methods have been proposed for the de-
convolution of gene expression data from heterogeneous biological samples, and these
methods can be loosely grouped into two categories: either deterministic or proba-
bilistic. Of the two, the deterministic approach is more popular. For instance, in
addition to the gene expression data, if the information about the cell-type specific
gene expression profiles is available, proportions of cellular types can be estimated
[150], for example, via linear regression [151–153], a very common technique for ana-
lyzing biological data [154]. On the other hand, if in addition to the gene expression
data, cellular proportions are known, then with linear regression, cell-type specific
gene expression profiles can be estimated [143, 155, 156]. Further, [157–159] investi-
gated the efficacy of the nonnegative matrix factorization (NMF) algorithms [160, 161]
for the “blind” deconvolution of gene expression data in the presence of additional
constraints, for example, some prior biological knowledge [157, 158]. Moreover, [162]
proposed a probabilistic approach based on the Markov chain Monte Carlo (MCMC)
method, assuming an availability of a good initial estimate of the cell type propor-
tions. All the approaches mentioned so far, either deterministic or probabilistic, made
one or more assumptions about the availability, either precise or a rough estimate, of
the cell type proportions or the cell-type specific profiles. But in reality, often times,
all we have is the heterogeneous gene expression data.
In this chapter, we propose a new probabilistic method, sequential Monte Carlo
(SMC) sampler [163–166] for static models to estimate the cell type proportions and
the cell-type specific expression profiles, given the heterogeneous gene expression data.
Specifically, we model the heterogeneous gene expression data using a Bayesian frame-
work where the cell-type specific expression profiles and the cell type proportions are
the unknown model parameters. We seek to approximate, in an efficient way, the pos-
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terior distributions of all the unknown model parameters by a set of weighted samples
(particles) from which their respective point estimates can be obtained. Bayesian in-
ference is an important area in the analyses of biological data [41, 167] as it provides
a complete picture of the uncertainty in the estimation of the unknown parameters
of a model given the data and the prior distributions for all the unknown model
parameters.
In particular, the SMC method is a class of sampling algorithms which combines
importance sampling and resampling. More importantly, the SMC framework for
static models is very similar to the sequential importance sampling (resampling) (SIS)
procedure for dynamic models [38], the only difference being the framework under
which the samples are propagated and this results in differences in the calculation of
the weights of the samples. In general, SMC allows us to treat, in a principled way,
any type of probability distribution, nonlinearity and non-stationarity [168, 169]. It
is easy to implement and applicable to very general settings. As noted in [163], SMC
algorithms address some of the major shortcomings of the MCMC-based algorithms:
(i) diagnosing convergence of a Markov chain (ii) requirement of burn-in period, and
(iii) MCMC algorithms getting trapped in local modes if the target distribution is
highly multi-modal. In addition, in big data analyses, unlike the MCMC approach,
SMC algorithms can be parallelized to reduce the computational time [163].
We compared the proposed SMC method with existing methods, including Dsec-
tion algorithm in [162] that is based on the MCMC approach and the recently
proposed probabilistic nonnegative matrix factorization (PNMF) algorithm [170], a
stochastic version of the deterministic NMF framework that takes into account the
stochastic nature of the gene expression data. Overall, in terms of the accuracy of
estimates of cell type proportions, cell-type specific gene expressions, and in addition,
in the identification of differentially expressed genes, the proposed method demon-
strated a superior performance. More importantly, the proposed method does not
require that we have an initial estimate of the cell type proportions or the cell-type
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specific expression profiles.
The remainder of this chapter is organized as follows. In Section 5.2, we present
the Materials and Methods. In Section 5.3, we investigate the performance of the
proposed method using simulated datasets artificially obtained from downloaded
pure tissues expression profiles and heterogeneous (impure) samples downloaded from
Affymetrix oligonucleotide arrays and GEO NCBI websites, the set of data that have
been employed to assess the performance of deconvolution algorithms. Finally, Sec-
tion Section 5.4 concludes the chapter.
In this chapter, we use the following notations:
1. p(·) and p(·|·) denote a probability and a conditional probability density func-
tions, respectively.
2. N (µ, λ−1) denotes the Gaussian probability density function with mean µ, pre-
cision λ and variance λ−1.
3. Gamma(α, β) denotes the Gamma probability density function with shape pa-
rameter α and rate parameter β.
4. U(a, b) denotes a uniform distribution with support x ∈ [a, b].
5. x and xT denote a column vector and its transpose, respectively.
6. X and Xˆ denote a matrix and its estimate, respectively.
5.2 Materials and methods
Let Y be an I × J gene expression matrix obtained from tissue samples with het-
erogeneous population, where I denotes the number of probes (or genes) in the mea-
surements and J denotes the total number of samples present. We assume that the
number of cell types, K, in the samples is known and each sample has the same
number of cell types present, but in varying percentages. Although, modeling the
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relationship between the expression value of pure and mixed samples is not strictly
linear, linearity has proved to be a reasonable and valid assumption in gene expression
deconvolution [143, 151, 162, 171]. As such, we follow the linear modeling approach
in analyzing the tissue samples. Denoting the indices of cell type, tissue sample and
gene by k, j and i, respectively, then the expression value of gene i in sample j is the




xikmkj + eij, i = 1, ..., I, j = 1, ..., J, (5.1)
where xik denotes the specific expression of gene i in cell type k, mkj denotes the
proportion of cell type k in sample j and eij is an additive Gaussian distributed noise
with zero mean and precision λ (inverse of variance). Instead of one gene at a time,
if all the genes are considered at once, then (5.1) can be written in a matrix form as
follows:
Y = XM + E, (5.2)
where Y denotes the I×J matrix of gene expression measurement from heterogeneous
samples, X denotes the unknown I ×K matrix of expression levels of the genes in all
the cell types (pure cell type expression signatures), M denotes the unknown K × J
matrix of cell type proportions and E is the additive noise matrix of dimension I×J .
Note that all elements of M are non-negative and each column sums to 1.
The goal of the inference is to obtain an estimate of the unknown matrices X
and M, which are the cell-type specific signatures and the cellular proportions, re-
spectively and in addition, an estimate of the precision λ, given the heterogeneous
gene expression matrix Y. To do this, we define a data generating model, impose
prior distributions on all the unknown model parameter, derive the sequence of tar-
get distributions for all the model parameters and finally, present the SMC algorithm
that estimates, in an efficient manner, the posterior distributions of all the unknown
model parameters.
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5.2.1 Likelihood function
As shown in (5.1), the data point for probe i in sample j i.e., yij, is modeled as
a sum of the cell-type specific expressions of probe i for all cell types, i.e. the ith
row of matrix X, denoted by xi,:, weighted by the proportions of all cell types in
sample j, i.e., the jth column of matrix M, denoted by m:,j plus an additive Gaussian
distributed noise, eij i.e.,








Further, if we assume independent and identically distributed (IID) measurements for








where θ = {λ, xik,mkj : i = 1, ..., I, j = 1, ..., J, k = 1, ..., K} are the unknown
parameters of the model that will be estimated.
5.2.2 Prior densities for all model parameters
Here, we present the prior distributions for all the unknown parameters in the model
in (5.4). With the prior distributions accurately specified and with the model in
(5.4), we can obtain the sequence of target distributions for all the unknown model
parameters.
5.2.2.1 Prior densities for the cell-type specific expressions
We model the specific expression of gene i in cell type k, xik with a Gaussian dis-
tribution, i.e., xik ∼ N (µik, ν−1ik ), where µik and νik are the mean and precision,
respectively, and are assumed known [162, 170]. Gaussian distribution is preferred so
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as to make use of the property of conjugate priors, i.e., the sequence of target distri-
butions will remain Gaussian given that the prior and the likelihood distributions are
Gaussian [172]. Detailed derivations of the sequence of target distributions and the
choice of µik and νik are discussed in the Supplementary Material in [37].
5.2.2.2 Prior densities for the cell type proportions
We impose a Gaussian distribution on the proportion of cell type k in sample j,
mkj i.e, mkj ∼ N (µkj, ν−1kj ), where µkj and νkj are the mean and precision, respec-
tively, and are assumed known [170]. Although, other distributions can be considered,
surprisingly, Gaussian distribution performs well in our experiments. Detailed deriva-
tions of the sequence of target distributions and the how µkj and νkj are picked are
discussed in the Supplementary Material in [37].
5.2.2.3 Prior density for the precision
Gamma prior is placed on the inverse of the noise variance (precision), i.e, λ ∼
Gamma(α, β), with α and β assumed known. The choice of Gamma prior distri-
bution ensures that the sequence of target distributions for the precision parameter
will be Gamma distributions (conjugate prior property), given that the likelihood is
a Gaussian distribution [172]. Detailed derivations of the sequence of target distri-
butions and the choice of α and β are discussed in the Supplementary Material in
[37].
5.2.3 Sequential Monte Carlo samplers for Bayesian infer-
ence
5.2.3.1 General principle of SMC samplers.
Before we introduce the SMC sampler algorithm for gene expression decomposition,
we will succinctly describe the general principle of SMC samplers in Bayesian infer-
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ence settings [163–165]. Denote the prior distribution, the likelihood function and
the posterior distribution in a Bayesian inference setup as p(θ), p(Y|θ) and p(θ|Y),
respectively. Using the Bayes rule, the posterior distribution can be written as a







p(θ)p(Y|θ)dθ, a constant with respect to θ, is referred to as the
evidence. With SMC samplers, rather than sampling from the posterior distribution
p(θ|Y) in (5.5), a sequence of intermediate target distributions, {pit}Tt=1, are designed,
that transitions smoothly from the prior distribution, i.e., pi1 = p(θ), which is usually
easier to sample from, and gradually introduce the effect of the likelihood so that
in the end, we have piT = p(θ|Y) which is the posterior distribution of interest
[163, 164]. For such sequence of intermediate distributions, a natural choice is the




∝ p(θ)p(Y|θ)t , (5.6)
where {t}Tt=1 is a non-decreasing temperature schedule with 1 = 0 and T = 1,




p(θ)p(θ|Y)tdθ is the evidence at time t.
Next, we transform this problem in the standard SMC filtering framework [38] by
defining a sequence of joint target distributions up to and including time t, {p˜it}Tt=1








where the artificial kernels {Lb}t−1b=1 are referred to as the backward Markov ker-
nels, i.e., Lt(θt+1,θt) denotes the probability density of moving back from θt+1 to
θt [163, 164, 174]. However, it is often difficult to sample directly from the joint tar-
get distribution in (5.7). Instead, samples are obtained from another distribution,
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known as the importance distribution, with a support that includes the support of p˜it




Kf (θf−1,θf ), (5.8)
where {Kf}tf=2 are the Markov transition kernels or forward kernels, i.e., Kt(θt−1,θt)
denotes the probability density of moving from θt−1 to θt [163, 164].
Given that at time t− 1, we desire to obtain N random samples from the target
distribution in (5.7), but as discussed earlier, it is difficult to sample from the target
distribution and instead, we obtain the samples from the importance distribution
in (5.8). Following the principle of importance sampling, we then correct for the
discrepancy between the target and the importance distributions by calculating the
importance weights [38]. The unnormalized weights associated with the N samples

















, n = 1, ..., N.
(5.9)
As such, the set of weighted samples {θn1:t−1, wnt−1}Nn=1 approximates the joint target
distribution p˜it−1. To obtain an approximation to the joint target distribution at time
t, i.e, p˜it, the samples are first propagated to the next target distribution p˜it using a
forward Markov kernel Kt(θt−1,θt) to obtain the set of particles {θn1:t}Nn=1. Similar
to (5.9), we then correct for the discrepancy between the importance distribution
and the target distribution at time t. Thus, the unnormalized weights at time t are










































from the definitions of pit and pit−1 in (5.6) and noticing that












t ), n = 1, ..., N,
(5.10)
where {w˜nt−1}Nn=1 are the unnormalized weights at time t − 1, given in (5.9) and










, n = 1, ..., N. (5.11)
5.2.3.2 Resampling procedure
In the SMC procedure described above, after some iterations, all samples except one
will have very small weights, a phenomenon referred to as degeneracy in the literature.
It is unavoidable as it has been shown that the variance of the importance weights
increases over time [38]. An adaptive way to check this is by computing the effective





)2 [175]. To avoid degeneracy, one
performs resampling when the ESS is significantly less than the number of samples,
discarding the ineffective samples and then multiply the effective ones [40, 169]. In
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all our experiments, we performed resampling when the ESS is less than N/10 [44].
The resampling procedure is briefly summarized as follows:
• Interpret each weight wnt as the probability of obtaining the sample index n in
the set {θnt : n = 1, ..., N}.
• Draw N samples from the discrete probability distribution and replace the old
sample set with this new one.
• Set all weights to the constant value wnk = 1/N .
5.2.3.3 Target distributions, forward and backward kernels specification
for gene expression deconvolution
In (5.6) - (5.8), we need to specify the exact form of the sequence of target distributions
{pit}Tt=1, the forward kernels, {Kt}Tt=2 and the backward kernels {Lt−1}Tt=2 for the
problem of gene expression deconvolution.
• Sequence of target distributions and forward kernels: As earlier discussed, we
are interested in the likelihood tempered target sequence in (5.6). Here, we
present the sequence of target distributions for all the parameters in the model
presented in (5.4). Details of the derivations are in the Supplementary Material
in [37]. Define Yijk =
∑
k′ 6=k xik′mk′j, then the sequence of target distributions























k = 1, ..., K, j = 1, ..., J, t = 1, ..., T,
(5.12)
the sequence of target distributions for the cell-type specific expressions are given

























i = 1, ..., I, k = 1, ..., K, t = 1, ..., T,
(5.13)






















, t = 1, ..., T.
(5.14)
The optimal forward Markov kernel, in the sense of minimizing the variance of
the importance weights is Kt(θt−1,θt) = pit(θt) [163, 164]. In general, if pit is
not available in closed form (non-conjugate priors), then an MCMC kernel of
invariant distribution pit will be used for Kt (Metropolis-Hastings MCMC). For-
tunately, in our model, we are able to compute the sequence {pit}Tt=1 analytically
as shown in (5.12) - (5.14).
• Sequence of backward kernels: In order to obtain a good performance, the
backward kernel is optimized with respect to the forward kernel as this choice
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Algorithm 5 SMC Sampler Algorithm for Gene Expression Deconvolution.
1: Input: Heterogeneous gene expression matrix Y, α, β, {µkj, νkj : k = 1, ..., K, j =
1, ..., J}, {µik, νik : i = 1, ..., I, k = 1, ..., K}, and the temperature schedule 0 =
1 < 2... < T = 1 (See the Supplementary Material in [37] for the initial values)
2: for t = 1 : T do
3: if t = 1 then
4: for n = 1 : N do
5: Take a sample from Gamma(α, β)
6: for k = 1 : K do
7: for j = 1 : J do
8: Take a sample from N (µkj, ν−1kj )
9: end for
10: end for
11: for i = 1 : I do
12: for k = 1 : K do




17: Set wn1 = 1/N, n = 1, ..., N
18: else
19: Compute the unnormalized weights as follows using (5.17):
20: w˜nt = w
n
t−1p(Y|θt−1)(t−t−1), n = 1, ..., N






, n = 1, ..., N






and resample if ESS < N/10
24: Propagation of particles:
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25: for n = 1 : N do
26: Take a sample from pit(λ|·) in (5.14)
27: for k = 1 : K do
28: for j = 1 : J do
29: Take a sample from pit(mkj|·) in (5.12)
30: end for
31: end for
32: for i = 1 : I do
33: for k = 1 : K do













41: then the estimates of the cell type proportions matrix Mˆ, cell-type specific ex-
pression matrix Xˆ and the precision λˆ are obtained from θˆ for further analyses
(Note that each column of Mˆ is re-scaled to sum to unity)
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since it generally represents a good approximation of the optimal backward
kernel when the discrepancy between pit and pit−1 is small [164, 166]. Thus, the

















= p(Y|θnt−1)(t−t−1), n = 1, ..., N,
(5.17)
where t − t−1 is the step length of the cooling schedule of the likelihood at
time t. The derivation of the exact analytical expression in (5.17) for the gene
expression deconvolution problem is presented in the Supplementary Material
in [37].
Finally, since the unnormalized incremental weights in (5.17) at time t does not
depend on the particle values at time t but just on the previous particle set, the
particles {θnt }Nn=1 should be sampled after the weights {w˜nt }Nn=1 have been computed
and after the particle approximation {w˜nt ,θnt−1} has possibly been resampled [163].
The proposed algorithm for gene expression deconvolution is presented in Algorithm 5.
5.3 Results
5.3.1 Ground-truth for variables
We assessed the performance of the proposed method, which we will refer to as the
SMC method, on both simulated dataset and datasets that contain real mixed sam-
ples. For ease of exposition, denote Ytotal = [Y, Y˜], where matrix Ytotal is the down-
loaded matrix of pure and mixed gene expressions, matrix Y is the gene expression for
the heterogeneous/mixed samples and Y˜ is the gene expression matrix for the pure
samples (the expression profile of each sample often come in multiplicity, e.g., tech-
nical replicates). First, we compared the estimates of the cell types proportion and
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the cell-type specific expression matrices with some existing methods and secondly,
we went further to test the ability of the proposed method to identify differentially
expressed genes. Next, we present the “ground-truth” for all the unknown variables
in our analyses. Unless otherwise stated, all the datasets used in the analyses are not
log transformed.
5.3.1.1 Ground-truth for the cell types proportions and the cell-type spe-
cific expression profiles (matrices M and X)
For all datasets, “ground-truth” is available for the cell type proportions matrix
M. For the pure cell-type expression signatures, matrix X, “ground-truth” is com-
puted from the matrix Y˜, the gene expression for the pure samples. Denote Y˜ =
[Y˜1, Y˜2, ..., Y˜K ], where Y˜k, k ∈ {1, ..., K}, is the gene expression matrix that contains
replicate samples from pure cell type k, then, xik is computed as the mean of row i in
matrix Y˜k, that is, the mean expression for gene i across samples that contain only
cell type k.
5.3.1.2 List of differentially and non-differentially expressed genes
We produced the “ground-truth” for the list of differentially expressed and non-
differentially expressed genes from the “ground-truth” for the cell-type expression
signatures, matrix X, using the fold change rule (Although, the median fold change
proposed in [176] is theoretically a slightly better alternative to the mean fold change,
empirical results from both method are similar for all our datasets. More so, mean
fold change is better suited to our purpose because in the end, we estimate the mean
expression for each cell type [177]). For gene i, the fold change between cell types
r and u is defined as: FCi = max(xir, xiu)/min(xir, xiu), where xir and xiu are the
specific expressions of gene i in cell types r and u, r, u ∈ {1, ..., K} [176–178]. Thus,
given the specific expressions of gene i in cell types r, u ∈ {1, ..., K}, if FCi > 2, gene
i is said to be differentially expressed in the two cell types, otherwise no difference in
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expressions [179].
5.3.1.3 Cell types mapping and marker probesets
Estimates of the cell-type specific expression profiles obtained from any blind decom-
position algorithm require mapping to the correct cell types [157]. As such, marker
probesets are often employed to perform the mapping of the estimated profiles to the
true cell types. However, gene expression data are generated with different technolo-
gies (microarrays and RNA-seq) using equipment from different manufacturers (e.g.
Affymetrix, Illumina etc.). To avoid discrepancies that may arise in using probe-
set marker lists from another source due to probe annotation [180, 181], we defined
the list of marker probesets used in our experiments from the gene expression mea-
surements of pure cell types/tissues samples, i.e. matrix Y˜ and matrix X, following
the procedures highlighted in [157]. Details of how the marker probesets are defined
and the mapping of the estimated profiles to the true cell types are discussed in the
Supplementary Material in [37].
5.3.1.4 Metrics for comparing results
Notice that the mapping of estimated cell-type profiles to the true cell types also
rearranges the rows of the estimated proportions, matrix Mˆ. Now, to compare the
estimated variables with the true values, we compared the average mean absolute
difference for the simulated datasets and then calculated the Pearson correlation
coefficient (r) between the true value and the estimated value for the real data.
In addition, we tested if the proposed SMC method can identify differentially ex-
pressed genes between cell types. Given the “ground-truth” for the truly differentially
and non-differentially expressed genes, we computed, for each probeset, the expression
fold change between the columns of the estimated cell-type gene expression profiles,
matrix Xˆ. Specifically, between any two columns of matrix Xˆ and for each probeset
(and if cell type 1 is upregulated when compared to cell type 2 or vice-versa, sepa-
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rately), we computed the following by varying the fold change threshold from 1 to 5
in step of 0.25: true positives (TP), the number of correctly identified probes that are
truly differentially expressed; false positives (FP), the number of non-differentially
expressed probes but incorrectly identified as differentially expressed genes; false neg-
atives (FN), the number of truly differentially expressed genes but incorrectly iden-
tified as non-differentially expressed probes, and true negatives (TN), the number
of correctly identified non-differentially expressed probes. Further, we computed the
sensitivity or true positive rate (TPR) = TP/(TP+FN) and the false positive rate
(FPR), also defined as 1− specificity = FP/(FP+TN). With the TPR and the FPR
for the different threshold values, we generated the receiver operating characteristic
curves (ROC) for all pairs of cell types. Area under the ROC (AUROC) is obtained
for each plot. High value of AUROC (maximum is 1) indicates that the deconvolution
method is specific and sensitive in identifying differentially expressed probeset.
In addition, to compare our method with other existing gene expression deconvo-
lution methods that require same set of input data, we analyzed the datasets with
two other methods: another sampling algorithm developed by [162] which we will
refer to as the MCMC method and a recently developed probabilistic version of NMF
[170] which we will refer to as the PNMF method. Although, the MCMC method
assumes that a rough estimate of the mixing proportions might be available, in some
cases, in addition to the gene expression data, we initialized all methods with equal
cell type proportion in order to produce a fair comparison of the results. Also, for
the NMF method, cell-type specific gene expression profiles, matrix X is initialized
by drawing its entries from a uniform distribution U(0,max(Y)).
5.3.2 Simulated dataset
To test the proposed algorithm on simulated data, we created heterogeneous gene
expression datasets with varying number of samples from pure tissue samples. Specif-
ically, we downloaded the gene expression measurements (tissue specific gene expres-




Figure 5.1: Simulated datasets: (a) Plot of average MAD calculated from varying
the sample size for all the methods. (b) Plot of standard deviation of MAD for all
the methods.
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sion data) from the publicly available dataset series GSE1133, from the GEO website
[182] for human lung, heart and liver. Data preprocessing, that is, background adjust-
ment, normalization, and summarization were done with robust multi-array average
(RMA) procedure [183]. For the cell type proportion matrix M, each column of
the matrix is generated from a Dirichlet distribution. Heterogeneous gene expression
measurement is then created by multiplying the tissue specific gene expression pro-
files, matrix X by the simulated cell type proportions, matrix M. Finally, normally
distributed noise with mean zero and variance that is equal to the global variance in
gene expression between duplicate samples in GSE1133, is added. Then, we created
heterogeneous gene expression data, matrix Y that comprises of 10, 15, 20, 25, 30, 35
and 40 samples, respectively.
With each sample size, we made 25 experimental runs with each of the proposed
SMC algorithm, MCMC method and the PNMF method. For each of the methods
and a sample size, we record the mean absolute difference (MAD) between the true
cell type proportions and the estimated cell type proportions after each experimental
run and average MAD was computed after 25 runs. The results for the average and
the standard deviation of MAD for the three methods and all the sample sizes are
presented in Figure 5.1. In addition, for each sample size, we took the average of
the estimated standard deviations over the 25 experimental runs. For each sample
size, we showed, in Figure 5.2, a scatter plot of the standard deviations for the SMC
and the MCMC methods (PNMF algorithm returned only the maximum a posteriori
(MAP) estimates). Overall, the proposed SMC method outperforms its two other
counterparts across all the sample sizes, in terms of the accuracy of the estimates.
In addition, it can be seen that as the number of sample sizes goes up, estimates of
model parameters also improve.
Moreover, we investigated how much the results obtained from the proposed SMC
algorithm depends on the choice of the prior distributions. Specifically, we consid-
ered a Dirichlet distribution for modeling each column of the cell type proportions
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Figure 5.2: Plot of standard deviation of parameter estimates. Standard
deviation of the estimates obtained from the proposed SMC and MCMC methods.
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Table 5.1: Effect of the choice of priors for the proposed SMC algorithm.
SMC with conjugate priors SMC with non-conjugate priors
r 0.99 0.99
Runtime (minutes) 132 226
(non-conjugate prior), matrix M. With this choice of prior distribution, the sequence
of target distributions pit for the mixture proportions are no more in closed form as
we have in (5.12). Thus, to propagate the particles after the resampling procedure
in the proposed SMC algorithm, we employed an Metropolis-Hastings MCMC ker-
nel of invariant distribution pit [163]. For each particle, we ran 10 chains and the
last iteration is chosen as the propagated particle. On the GSE1133 dataset with 10
samples and 500 randomly chosen genes, the results obtained for the conjugate and
the non-conjugate prior distributions (Dirichlet distributions) are shown in Table 5.1.
Particularly, we recorded the correlation coefficient (r) and the runtime for the two
cases on a 3.5 Ghz Intel 8 processors running MATLAB. From Table 5.1, the two
cases yielded similar results in terms of the accuracy of the estimates, but the algo-
rithm implemented with the non-conjugate priors is slower than its counterpart with
conjugate priors. This is due to the fact that the MCMC kernel used in propagating
the particles ran multiple iterations for each particle, and the similarity in the results
is because the MCMC kernel used has an invariant distribution pit, where the particles
are sampled from.
Lastly, on the same dataset, we performed experiments with the MCMC method
and the PNMF algorithm. In particular, the MCMC was run with chain length of
40, 000, with the initial 20000 as burn-in and a thinning interval of 20. The results
are shown in Table 5.2
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Table 5.2: Runtime of different methods on the same dataset.
SMC method MCMC method PNMF method
Runtime (minutes) 132 116 84
r 0.99 0.93 0.95
5.3.3 Affymetrix dataset: 2 cell types
Next, we evaluated the performance of the proposed SMC algorithm on a tissue
mixture oligonucleotide microarray probe-level dataset from Affymetrix previously
analyzed by [162]. Data preprocessing were done by the RMA procedure [183]. This
dataset, Ytotal, consists of heterogeneous expressions from human brain and heart
cells. There are 33 samples and each sample comprises of specific proportions of the
two distinct cell types. The true mixture proportions are shown in the Supplementary
Material in [37] where the samples are designated S1,...,S33 for sample 1,...,sample
33, respectively. Samples S1 - S3 and S31 - S33, samples from the pure cell types,
constitute the matrix Y˜, for approximating the “ground-truths” for the cell-type
expression profiles (matrix X), marker probesets and the list of truly differentially
expressed and non-differentially expressed genes. Samples S4 - S30 constitute the
heterogeneous gene expression matrix Y that was analyzed.
First, we analyzed the heterogeneous gene expression matrix Y with the SMC
method and the plot of the estimated proportions, matrix Mˆ versus the true propor-
tions, matrix M is shown in Figure 5.3 (a) with the Pearson correlation coefficient,
r = 0.99. In Table 5.3, we record the correlation between the true and the estimated
cell-type specific expression profiles for all the cell types. Further, we test the power
of the SMC method to detect truly differentially expressed and non-differentially
expressed genes between cell types. Figures 5.4 (a) and (b) show the ROCs gener-
ated with the SMC method and the AUROC for each plot is recorded in Table 5.3.
Moreover, we analyzed the same dataset with the MCMC method and the PNMF





Figure 5.3: Plot of proportions for the Affymetrix dataset. Plot of the true
proportions vs. estimated proportions obtained from: (a) the proposed SMC method,
(b) the MCMC method, and (c) the PNMF method.
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Table 5.3: Pearson correlation coefficient (r) and AUROC for the Affymetrix dataset
(AUROC in columns 3 and 4).
rM rB rH Brain > Heart Heart > Brain
SMC 0.99 0.98 0.98 0.99 0.98
MCMC 0.93 0.92 0.94 0.91 0.92
PNMF 0.95 0.95 0.95 0.96 0.94
rM , rB and rH denote the Pearson correlation coefficients between the true and the
estimated: (i) cell types proportions, (ii) the brain cell expression profiles, and (iii)
the heart cell expression profiles, respectively. In columns 5 and 6, Brain > Heart,
for example, implies that brain is upregulated as compared to heart.
algorithms and the results are presented in Figures 5.3 (b) and (c), and in Table 5.3.
The results obtained and presented in Table 5.3 show that the proposed SMC method
accurately estimates cell type proportions, cell-type specific expressions and in fact,
more specific in identifying the differentially expressed genes when compared to the
other two methods.
5.3.4 GEO series GSE19830 dataset: 3 cell types
In the mixture experiment by [143], tissue samples from the liver, brain and lung of
a single rat were analyzed using Affymetrix expression arrays. Biospecimens from
the three different tissues were mixed in different proportions (mixture proportion of
each sample is shown in the Supplementary Material in [37]). The data consists of
11 different mixtures, each mixture with 3 technical replicates. In addition, there are
9 samples for the pure tissues (S1 - S9), 3 technical replicates for each pure tissue
type. We downloaded the dataset from the NCBI GEO website and performed data
preprocessing with the RMA.
We analyzed the heterogeneous gene expression matrix with the SMC method




Figure 5.4: Affymetrix dataset: (a) Brain > Heart. ROC plot obtained from the
proposed SMC method for brain vs. heart cell types, brain upregulated. (b) Heart
> Brain. ROC plot obtained from the proposed SMC method for brain vs. heart
cell types, heart upregulated.
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Table 5.4: Pearson correlation coefficient (r) for the GSE19830 dataset.
rM rLi rBr rLu
SMC 0.99 0.98 0.95 0.98
MCMC 0.91 0.90 0.91 0.89
PNMF 0.94 0.93 0.93 0.94
rM , rLi, rBr and rLu denote the Pearson correlation coefficients between the true
and the estimated: (i) cell types proportions, (ii) the liver cell expression profiles,
(iii) the brain cell expression profiles, and (iv) the lung cell expression profiles,
respectively.
and the plot of the estimated proportions, matrix Mˆ versus the true proportions,
matrix M is shown in Figure 5.5 (a) with the Pearson correlation coefficient, r = 0.99
(similar results are obtained for the MCMC and the PNMF methods in Figures 5.5
(b) and (c)). In addition, we record the correlation between the true and the esti-
mated cell-type specific expression profiles in Table 5.4. Next, on this dataset, we
test the power of the SMC method to detect truly differentially expressed and non-
differentially expressed genes between cell types. Figures 5.6 (a), (b) and (c) (and in
the Supplementary Material in [37]) show the ROCs generated with the SMC method
and the AUROC for each plot is recorded in Table 5.5. Moreover, we analyzed same
dataset with the MCMC method and the PNMF algorithm and the results for the
correlations and AUROC are presented in Table 5.4 and Table 5.5, respectively. The
results obtained show that the proposed SMC method accurately estimates cell type
proportions, cell-type specific expressions and in fact, more specific in identifying the
differentially expressed and non-differentially expressed genes when compared to the
two other methods.





Figure 5.5: Plots of proportions for GSE19830 dataset. Plot of the true pro-
portions vs. estimated proportions obtained from: (a) the proposed SMC method (b)
the MCMC method (c) the PNMF method.





Figure 5.6: GSE19830 dataset. ROC plot obtained from the proposed SMC method
for: (a) liver vs. brain cell types, liver upregulated (Liver > Brain) (b) liver vs.
lung cell types, liver upregulated (Liver > Lung) (c) brain vs. lung cell types, brain
upregulated (Brain > Lung).
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Table 5.5: AUROC for the GSE19830 dataset.
Liver > Brain Liver > Lung Brain > Lung Liver < Brain Liver < Lung Brain < Lung
SMC 0.98 0.98 0.98 0.98 0.97 0.98
MCMC 0.90 0.89 0.91 0.88 0.90 0.91
PNMF 0.93 0.94 0.94 0.93 0.95 0.95
For example, Liver > Brain implies that liver is upregulated as compared to brain.
5.3.5 GEO series GSE11058 dataset: 4 cell types
In the real mixtures with 2 and 3 cell types, expression differences between different
cell types are relatively higher compared to the expression differences between cell
types within a tissue sample. Hence, we tested the proposed algorithm on real tissue
samples that are composed of cell types with gene expression profiles that are more
similar to each other. Specifically, we analyzed a publicly available dataset from the
GEO series GSE11058, downloaded from the NCBI GEO [184] and data preprocessing
was done by RMA. Each heterogeneous sample in the data comprises of 4 different
cell lines of immune origin, namely: Jurkat (J), IM-9 (I), Raji (R) and THP-1 (T).
In total, there are 24 samples in the dataset, that is, triplicates of each pure cell type
and four different mixtures for which the relative proportions of each cell type are
known, as shown in Table C in the Supplementary Material in [37] where samples
are designated S1,...,S24 for sample 1,...,sample 24, respectively. The first 12 samples,
samples from pure cell types constitute the matrix Y˜, which is used for approximating
the “ground-truths” for the cell-type expression profiles (matrix X), marker probesets
and the list of truly differentially expressed and non-differentially expressed genes.
Samples S13 - S24 constitute the heterogeneous gene expression matrix Y that
we analyzed with the proposed SMC method, the MCMC method and the PNMF
method. Figures 5.7 (a), (b) and (c) and Table 5.6 show the correlation values ob-
tained between the estimated cellular proportions and the true proportions, and then
the estimated cell-type specific expression profiles and the true expression profiles. In
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Table 5.6: Pearson correlation coefficient (r) for the GSE19830 dataset.
rM rJ rI rR rT
SMC 0.99 0.97 0.98 0.98 0.96
MCMC 0.91 0.90 0.90 0.91 0.92
PNMF 0.94 0.93 0.95 0.93 0.94
rM , rJ , rI , rR, and rT denote the Pearson correlation coefficients between the true
and the estimated: (i) cell types proportions, (ii) the Jurkat cell expression profiles,
(iii) the IM-9 cell expression profiles, (iv) the Raji cell expressions profiles, and (iv)
the THP-1 cell expression profiles, respectively.
Table 5.7: AUROC for the GSE19830 dataset.
J>I J>R J>T I>R I>T R>T J<I J<R J<T I<R I<T R<T
SMC 0.98 0.93 0.83 0.93 0.89 0.93 0.92 0.90 0.87 0.95 0.96 0.96
MCMC 0.90 0.89 0.91 0.88 0.90 0.91 0.92 0.91 0.91 0.89 0.92 0.91
PNMF 0.93 0.94 0.94 0.93 0.95 0.92 0.94 0.94 0.94 0.93 0.95 0.95
J = Jurkat; I = IM-9; R = Raji; T = THP-1. For example, J > I implies that
Jurkat is upregulated as compared to IM-9.
addition, AUROC for all methods is shown in Table 5.7 and the ROC plots obtained
for the proposed SMC method are shown in Figures 5.8 (a), (b) and (c) and in the
Supplementary Material in [37]. Again, the SMC method outperformed the MCMC
method and the PNMF method in terms of the accuracy of the cellular proportions
estimates and the cell-type specific expression estimates, and finally, in identifying
differentially and non-differentially expressed genes.





Figure 5.7: Plot of proportions for GSE11058 dataset. Plot of the true propor-
tions vs. estimated proportions obtained from (a) the proposed SMC method (b) the
proposed MCMC method (c) the proposed PNMF method.





Figure 5.8: GSE11058 dataset. ROC plot obtained from the proposed SMC method
for: (a) Jurkat vs. IM-9 cell types, Jurkat upregulated (Jurkat > IM-9) (b) Jurkat
vs. Raji cell types, Jurkat upregulated (Jurkat > Raji) (c) Jurkat vs. THP-1 cell
types, Jurkat upregulated (Jurkat > THP-1).
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5.4 Discussion
In this chapter, we modeled the heterogeneous gene expression data using a Bayesian
framework. Specifically, we modeled the expression of a gene in each sample as
the sum of expressions of that gene in all the constituting cell types in the sample,
weighted by the proportions of all cell types in the sample plus an additive Gaussian
noise.
We proposed an efficient SMC algorithm, a novel Bayesian approach that is based
on sampling technology suited for approximating the posterior distributions of com-
plex model parameters. In this chapter, we obtained the estimates of the cellular
proportions (matrix M) and the cell-type specific expression profiles (matrix X) from
the heterogeneous gene expression data. Further, the estimated expression profiles
are used to identify genes that are differentially expressed which is one of the ma-
jor reasons for carrying out gene expression deconvolution analysis. In addition to
the identification of the differentially expressed genes, performing the complete gene
expression deconvolution is an attractive method that provides an alternative to the
very expensive and time consuming manual approaches like LCM and flow cytometry
for separating cells which often lead to an altered cell-type specific gene expression
profiles. Unlike some previously proposed methods for gene expression data deconvo-
lution, our method does not rely on any prior knowledge of the cell type proportions
or the cell-type specific gene expression profiles.
In testing the performance of the proposed SMC method, we evaluated the method
on simulated datasets and publicly available real datasets. From the results obtained
in all the experiments, the proposed SMC method demonstrated a superior perfor-
mance in terms of accuracy of the estimated model parameters and also in identifying
differentially expressed genes as shown in the Results Section and in the Supplemen-
tary Material in [37], when compared to the two other methods.
Moreover, in mapping the estimated cell-type specific profiles (matrix Xˆ) to the
true cell types, we defined a set of marker probesets which were defined from the gene
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expression data from pure samples, matrix Y˜. Although in the real settings, we have
no access to these pure samples, a small number of cell-type specific markers are often
available, for instance, [185] identified a set of markers for different immune subsets.
Finally, it was shown that PNMF and the MCMC methods are faster than the
SMC method in terms of computational speed. However, when there is an option
of parallelization of computational resources, the SMC method can be considerably
improved in terms of the computational time.
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Chapter 6
Conclusions
In this thesis, we have addressed various problems in the field of Computational
biology. In particular, we looked at the characterization of intra-tumor heterogeneity
in tumor samples by taking cognizance of mutational and structural variabilities;
inference of GRN from measurement with missing values and the deconvolution of
heterogeneous gene expression data.
In the first part (Chapters 2 and 3), we presented computational methods for
resolving the inherent heterogeneity in tumor samples. Our approach involves a
state-space formulation of the feature allocation modeling frameworks. In Chapter
2, making copy-neutrality assumption, our novel algorithm for inferring subclonal
structure in cancer estimates the mutational profile of the cancer cell subpopulations
and their respective proportions in the tumor samples. In Chapter 3, relaxing the
copy-neutrality assumption and considering structural variability such as CNV in our
modeling strategy, our novel algorithm estimates the number of tumor subclones,
the subclonal variant copy numbers, subclonal total copy numbers and subclonal
proportions in tumor samples. By design, these algorithms are capable of handling
any number of mutations. More importantly, whenever data from newly probed
genomic locations are available, the existing estimates of model parameters can be
refined without analyzing the entire dataset, a feature that existing solutions do not
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possess. Via extensive simulations, the proposed methods exhibit high accuracy, in
most cases, and compare favorably with existing methods. Results on real tumor
samples reveal driver mutation events specific to cancer types, and indicate clonal
expansion by manual phylogenetic analysis.
Further, in the second part (Chapters 4 and 5), we presented computational meth-
ods for inferring GRN and performing GED from gene expression data. Specifically, in
Chapter 4, we examined the problem of re-engineering GRN from measurement with
missing values using a state-space modeling framework such that our measurement
model incorporates the effect of the missing data points. With missing measurements,
our method produced a better inference of the model parameters and hence, more
accurate prediction of the underlying GRN than other methods that require complete
gene expression matrix as input. In Chapter 5, we solved the problem of deconvolv-
ing the heterogeneous gene expression data into cell-type specific expressions and cell
type proportions using a Bayesian modeling framework. We treated the cell type pro-
portions and the cell-type specific expressions as the parameters of the model. Our
proposed algorithm is evaluated on simulated datasets and publicly available real
datasets: Affymetrix oligonucleotide arrays and NCBI GEO. The results obtained on
all datasets showed a superior performance with an improved accuracy in the estima-
tion of cell type proportions and the cell-type specific expressions, and in addition,
more accurate identification of differentially expressed genes when compared to the
state-of-the-art method.
In our work on the characterization of intra-tumor heterogeneity (Chapters 2 and
3), we described methods to resolve intra-tumor heterogeneity, one of the two types of
tumor heterogeneity. In the future, we will be exploring inter-tumor heterogeneity, the
other arm of tumor heterogeneity. Doing this will help us to adequately characterize
the differences that are observed among individuals that suffer from the same type
of cancer. Also, in our work presented in this thesis, we mainly made use of somatic
mutation datasets. In the future, we are looking to build statistical models and
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computational algorithms that jointly analyze:
• RNA-Seq and DNA sequencing data
• copy number variation and somatic mutation data.
We hope that combining these diverse set of data may reveal better signal and ensure
more accurate characterization of tumor heterogeneity.
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